var title_f14_11_14512="Amiodarone toxicity chest radiograph";
var content_f14_11_14512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Amiodarone pulmonary toxicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs from a patient treated with amiodarone demonstrate left upper lobe consolidation (A) and six months later right upper lobe consolidation with residual scar in left upper lobe (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14512=[""].join("\n");
var outline_f14_11_14512=null;
var title_f14_11_14513="Arm curl exercise";
var content_f14_11_14513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F58676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F58676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise: Arm curl",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After a few weeks of doing this exercise for your upper arm muscles, lifting that gallon of milk will be much easier.",
"    <ol>",
"     <li>",
"      Stand with your feet shoulder-width apart.",
"     </li>",
"     <li>",
"      Hold weights* straight down at your sides, palms facing forward. Breathe in slowly.",
"     </li>",
"     <li>",
"      Breathe out as you slowly bend your elbows and lift weights toward chest. Keep elbows at your sides.",
"     </li>",
"     <li>",
"      Hold the position for 1 second.",
"     </li>",
"     <li>",
"      Breathe in as you slowly lower your arms.",
"     </li>",
"     <li>",
"      Repeat 10-15 times.",
"     </li>",
"     <li>",
"      Rest; then repeat 10-15 more times.",
"     </li>",
"    </ol>",
"    As you progress, use a heavier weight and alternate arms until you can lift the weight comfortably with both arms.",
"    <div class=\"footnotes\">",
"     * Hand-held weights or household items (soup cans, bottles of water).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14513=[""].join("\n");
var outline_f14_11_14513=null;
var title_f14_11_14514="Antipyrine and benzocaine: Pediatric drug information";
var content_f14_11_14514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antipyrine and benzocaine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/51/11060?source=see_link\">",
"    see \"Antipyrine and benzocaine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42963?source=see_link\">",
"    see \"Antipyrine and benzocaine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15070561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aurodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F135881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Auralgan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Otic Agent, Analgesic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Otic Agent, Cerumenolytic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/51/11060?source=see_link\">",
"      see \"Antipyrine and benzocaine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infants, Children, and Adults: Otic: Fill ear canal; moisten cotton pledget, place in external ear, repeat every 1-2 hours until pain and congestion is relieved; for ear wax removal instill drops 3-4 times/day for 2-3 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F135872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, otic [drops]: Antipyrine 5.4% and benzocaine 1.4% (10 mL, 15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aurodex&trade;: Antipyrine 5.4% and benzocaine 1.4% (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F135862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of pain and reduction of inflammation associated with acute congestive and serous otitis media, swimmer's ear, otitis externa; facilitates ear wax removal",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F135893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adverse reactions are reported in the manufacturer&rsquo;s labeling. Refer to Benzocaine monograph.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to antipyrine, benzocaine, or any component; perforated tympanic membrane",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of otic anesthetics may mask symptoms of a fulminating middle ear infection (acute otitis media); not intended for prolonged use",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F135868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5093459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez LF, Smolik LM, and Zbehlik AJ, &ldquo;Benzocaine-Induced Methemoglobinemia: Report of a Severe Reaction and Review of the Literature,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1994, 28(5):643-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?14/11/14514/abstract-text/8069004/pubmed\" id=\"8069004\" target=\"_blank\">",
"        8069004",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12771 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14514=[""].join("\n");
var outline_f14_11_14514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15070561\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135881\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045235\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045233\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135872\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135862\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045237\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135893\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045239\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045232\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298761\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218031\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135868\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5093459\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/51/11060?source=related_link\">",
"      Antipyrine and benzocaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/61/42963?source=related_link\">",
"      Antipyrine and benzocaine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14515="Patient information: Latest medicines to prevent blood clots (The Basics)";
var content_f14_11_14515=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1075\">",
"         Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/32/24067\">",
"         Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/21/6483\">",
"         Patient information: Reducing the costs of medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/55/24435\">",
"         Patient information: Stroke (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/44/2755\">",
"         Patient information: Warfarin (Coumadin) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/44/12998\">",
"         Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/29/2517\">",
"         Patient information: Pulmonary embolism (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/61/32726\">",
"         Patient information: Reducing the costs of medicines (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/15/21747\">",
"         Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Latest medicines to prevent blood clots (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H555733454\">",
"      <span class=\"h1\">",
"       What are the latest medicines to prevent blood clots?",
"      </span>",
"      &nbsp;&mdash;&nbsp;These medicines include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"       dabigatran",
"      </a>",
"      (brand name: Pradaxa),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      (brand name: Xarelto), and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/40/34436?source=see_link\">",
"       apixaban",
"      </a>",
"      (brand name in Canada: Eliquis). They are prescription medicines that make your blood less likely to clot. They are also known as &ldquo;blood thinners&rdquo; and &ldquo;anti-clotting medicines.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555733471\">",
"      <span class=\"h1\">",
"       How are the latest anti-clotting medicines different from older ones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"       Dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      , and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/40/34436?source=see_link\">",
"       apixaban",
"      </a>",
"      work as well or slightly better than",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      (brand name: Coumadin). Warfarin is an older medicine that also helps prevent blood clots.",
"     </p>",
"     <p>",
"      People who take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      need frequent blood tests to make sure they are taking the right amount. They also need to be careful about eating the same amount of vitamin K on a regular basis. Vitamin K is found in leafy greens and other vegetables. People who take the newer medicines don&rsquo;t need to do those 2 things.",
"     </p>",
"     <p>",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       Warfarin",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      are taken once a day.",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"       Dabigatran",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/40/34436?source=see_link\">",
"       apixaban",
"      </a>",
"      are taken twice a day.",
"     </p>",
"     <p>",
"      These newer medicines cost more than",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/2/33830?source=see_link\">",
"       warfarin",
"      </a>",
"      . That might not be a problem if they are covered by your insurance plan. But if they are not, warfarin is still a good choice, even though it is less convenient because of the needed blood testing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555733488\">",
"      <span class=\"h1\">",
"       Why might my doctor prescribe the latest anti-clotting medicines?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors prescribe",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"       dabigatran",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      to people who have a heart rhythm problem called &ldquo;atrial fibrillation.&rdquo; In people with this condition, the medicine helps lower the risk of stroke.",
"     </p>",
"     <p>",
"      Doctors prescribe",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?13/41/13973?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?33/40/34436?source=see_link\">",
"       apixaban",
"      </a>",
"      to people who have had a hip or knee replaced. These medicines help lower the risk of a blood clot in the legs (called a &ldquo;deep vein thrombosis&rdquo; or &ldquo;DVT&rdquo;) or the lungs (called a &ldquo;pulmonary embolism&rdquo;).",
"     </p>",
"     <p>",
"      Your doctor might order blood tests to check your kidney function. If you have or develop kidney trouble, these newer medicines might not be right for you.",
"     </p>",
"     <p>",
"      If you take 1 of the newer medicines to prevent blood clots, there are certain things you should do. These are described below.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Store",
"        </strong>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"         dabigatran",
"        </a>",
"        <strong>",
"         pills in the bottle",
"        </strong>",
"        <strong>",
"         they came in &ndash;",
"        </strong>",
"        Do not put this medicine in any other container, such as a pill box or pill organizer. After you open the bottle, use the pills within 4 months.",
"       </li>",
"       <li>",
"        <strong>",
"         Do not break, chew, or open the",
"        </strong>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"         dabigatran",
"        </a>",
"        <strong>",
"         capsules",
"        </strong>",
"        <strong>",
"         &ndash;",
"        </strong>",
"        This can change the strength of the medicine.",
"       </li>",
"       <li>",
"        <strong>",
"         Take your medicine as directed",
"        </strong>",
"        &ndash; It is very important to take these medicines exactly as your doctor tells you to. Take them at the same time each day and do not skip any doses. Do not take 2 doses at once, change the dose, or stop taking this drug without talking to your doctor. Do not take medicines to prevent blood clots with grapefruit or grapefruit juice, which can change their effects. Take",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?0/58/933?source=see_link\">",
"         dabigatran",
"        </a>",
"        with food to lessen the chance of an upset stomach.",
"       </li>",
"       <li>",
"        <strong>",
"         Ask your doctor before taking any new medicines -",
"        </strong>",
"        These include prescription medicines, over-the-counter medicines, and herbal medicines. Certain medicines (especially antibiotics and St. John&rsquo;s wort) might change the effects of the newer anti-clotting medicines.",
"       </li>",
"       <li>",
"        <strong>",
"         Wear a medical alert tag -",
"        </strong>",
"        Always wear a bracelet, necklace, or another kind of alert tag that warns people that you take an anti-clotting medicine and why. That way, if you are in an accident and are unable to explain your condition, responders will know how to care for you. Your alert tag should also have the name and phone number of an emergency contact.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555733527\">",
"      <span class=\"h1\">",
"       What are the side effects of the newer medicines to prevent blood clots?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common side effect is bleeding from any part of your body. The bleeding can be minor or sometimes serious. This even includes inside your body, where you cannot see it.",
"     </p>",
"     <p>",
"      Call your doctor RIGHT AWAY if you took more medicine than you were supposed to or if you have any of these possible signs of bleeding:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Feel sick to your stomach or throwing up blood or something that looks like coffee grounds",
"       </li>",
"       <li>",
"        Headaches, dizziness, and weakness",
"       </li>",
"       <li>",
"        Nosebleeds",
"       </li>",
"       <li>",
"        Dark red or brown urine",
"       </li>",
"       <li>",
"        Blood in your bowel movements, or dark-colored bowel movements",
"       </li>",
"       <li>",
"        Pain and swelling after an injury",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also call you doctor if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleed from your gums after brushing your teeth",
"       </li>",
"       <li>",
"        Swell or have pain where you got an injection (shot)",
"       </li>",
"       <li>",
"        Have heavy menstrual periods or bleeding between periods",
"       </li>",
"       <li>",
"        Have diarrhea, vomit, or are unable to eat for more than 24 hours",
"       </li>",
"       <li>",
"        Have a fever (temperature higher than 100.4&ordm; F or 38&ordm; C)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555733545\">",
"      <span class=\"h1\">",
"       Is there anything I can do to lower the risk of bleeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a soft bristle toothbrush",
"       </li>",
"       <li>",
"        Floss with waxed floss (not unwaxed floss)",
"       </li>",
"       <li>",
"        Shave with an electric razor rather than a razor blade",
"       </li>",
"       <li>",
"        Take care when using sharp objects, such as knives and scissors",
"       </li>",
"       <li>",
"        Avoid doing things might make you likely to fall, such as walking on slippery surfaces or climbing on a high stool",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For more detailed information about your medicines, ask your doctor or nurse for information from Lexicomp available through UpToDate. The Lexicomp hand-outs explain how to use and store your medicines. They also list possible side effects and warn you if your medicines should not be taken with certain other medicines or foods.&nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H555733562\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=see_link\">",
"       Patient information: Stroke (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=see_link\">",
"       Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=see_link\">",
"       Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=see_link\">",
"       Patient information: Reducing the costs of medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=see_link\">",
"       Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       Patient information: Pulmonary embolism (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=see_link\">",
"       Patient information: Reducing the costs of medicines (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?14/11/14515?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86638 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-42AE1A7C96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14515=[""].join("\n");
var outline_f14_11_14515=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733454\">",
"      What are the latest medicines to prevent blood clots?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733471\">",
"      How are the latest anti-clotting medicines different from older ones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733488\">",
"      Why might my doctor prescribe the latest anti-clotting medicines?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733527\">",
"      What are the side effects of the newer medicines to prevent blood clots?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733545\">",
"      Is there anything I can do to lower the risk of bleeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H555733562\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/3/1075?source=related_link\">",
"      Patient information: Deep vein thrombosis (blood clots in the legs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/32/24067?source=related_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/61/32726?source=related_link\">",
"      Patient information: Reducing the costs of medicines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/21/6483?source=related_link\">",
"      Patient information: Reducing the costs of medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14516="Pediatric lumbar puncture technique";
var content_f14_11_14516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spinal needle placement using one or two hands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14516=[""].join("\n");
var outline_f14_11_14516=null;
var title_f14_11_14517="ANLL FAB M3";
var content_f14_11_14517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myeloid leukemia (AML FAB M3, acute promyelocytic leukemia, hypergranular variant)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with AML of the M3 variant. The blasts contain large numbers of azurophilic cytoplasmic granules, which almost obscure the nuclear outlines. (Wright-Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14517=[""].join("\n");
var outline_f14_11_14517=null;
var title_f14_11_14518="Chapter 2A: Glomerular anatomy and function";
var content_f14_11_14518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 2A: Glomerular anatomy and function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14518/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/11/14518/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 10, 2001.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood flow to the kidneys averages 20 percent of the cardiac output. In terms of flow per 100 g weight, the renal blood flow (RBF) is four times greater than that to the liver or exercising muscle and eight times that of coronary blood flow. Blood enters the kidney through the renal arteries and passes through serial branches (interlobar, arcuate, interlobular) before entering the glomeruli via the afferent arterioles. The portion of the plasma not filtered across the glomerular capillary wall then leaves the glomeruli via the efferent arterioles and enters the postglomerular capillaries. In the cortex, these capillaries run in apposition to the adjacent tubules, although not necessarily to the tubule segments from the same glomerulus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, branches from the efferent arterioles of the juxtamedullary glomeruli enter the medulla and form the vasa recta capillaries (",
"    <a class=\"graphic graphic_figure graphicRef65665 \" href=\"UTD.htm?12/63/13296\">",
"     figure 1",
"    </a>",
"    ). Blood returns to the systemic circulation through veins similar to the arteries in name and location.",
"   </p>",
"   <p>",
"    The renal circulation affects urine formation in the following ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of glomerular filtration is an important determinant of solute and water excretion.",
"     </li>",
"     <li>",
"      The peritubular capillaries in the cortex return reabsorbed solutes and water to the systemic circulation and can modulate the degree of proximal tubular reabsorption and secretion (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=see_link\">",
"       \"Chapter 3A: Cell model for proximal transport\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The vasa recta capillaries in the medulla return reabsorbed salt and water to the systemic circulation and participate in the countercurrent mechanism, permitting the conservation of water by the excretion of a hyperosmotic urine (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=see_link\">",
"       \"Chapter 4B: Countercurrent mechanism\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The remainder of this chapter will review glomerular function, the factors responsible for the regulation of the glomerular filtration rate (GFR) and renal plasma flow, and the clinical methods used to measure these parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOMERULAR ANATOMY AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerulus consists of a tuft of capillaries that is interposed between the afferent and efferent arterioles. Each glomerulus is enclosed within an epithelial cell capsule (Bowman's capsule) that is continuous both with the epithelial cells that surround the glomerular capillaries and with the cells of the proximal convoluted tubule (",
"    <a class=\"graphic graphic_figure graphicRef58117 \" href=\"UTD.htm?12/39/12913\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus, the glomerular capillary wall, through which the filtrate must pass, consists of three layers: the fenestrated endothelial cell, the glomerular basement membrane (GBM), and the epithelial cell. The epithelial cells are attached to the GBM by discrete foot processes. The pores between the foot processes (slit pores) are closed by a thin membrane called the slit diaphragm, which functions as a modified adherens junction (",
"    <a class=\"graphic graphic_figure graphicRef58117 \" href=\"UTD.htm?12/39/12913\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The GBM is a fusion product of basement membrane material produced by the glomerular epithelial and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The GBM performs a variety of functions including maintenance of normal glomerular architecture, anchoring adjacent cells, and acting as a barrier to the filtration of macromolecules. It consists of the following major constituents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type IV collagen, which forms cords that provide the basic superstructure of the GBM",
"     </li>",
"     <li>",
"      The spaces between the cords are filled by a variety of substances including laminin, nidogen, and heparan sulfate proteoglycans [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/6\">",
"       6",
"      </a>",
"      ]. Laminin and nidogen form a tight complex, one of the major functions of which is cell adhesion to the GBM. In comparison, anionic heparan sulfate proteoglycans is largely responsible for the charge barrier to the filtration of anionic macromolecules (see below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An abnormality in type IV collagen is responsible for the disorder hereditary nephritis (Alport's syndrome), which is a progressive form of glomerular disease (at least in males) that is often associated with hearing loss and lenticular abnormalities. The primary defect in almost all patients appears to reside in the noncollagenous domain of type IV collagen, involving the gene coding for the alpha-5 chain which is located on the X chromosome, the COL4A5 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Abnormalities in the alpha-3 and alpha-4 chains of type IV collagen may also cause hereditary nephritis, which is not surprising since the alpha-3, -4, and -5 chains combine to form a novel collagen that is expressed in the glomerulus and a few other tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Filtration barrier and protein excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major functions of the glomerulus is to allow the filtration of small solutes (such as sodium and urea) and water, while restricting the passage of larger molecules (",
"    <a class=\"graphic graphic_figure graphicRef58980 \" href=\"UTD.htm?6/62/7151\">",
"     figure 3",
"    </a>",
"    ). Solutes up to the size of inulin (mol wt 5200) are freely filtered. On the other hand, myoglobin (mol wt 17,000) is filtered less completely than inulin, while albumin (mol wt 69,000) is filtered only to a minor degree. Filtration is also limited for ions or drugs which are bound to albumin, such as roughly 40 percent of the circulating calcium.",
"   </p>",
"   <p>",
"    This difference in filtration of solutes is important physiologically. The free filtration of sodium, potassium, and urea, for example, allows the kidney to maintain the steady state by excreting the load derived from dietary intake and endogenous metabolism. On the other hand, the restricted filtration of larger proteins prevents such potential problems as negative nitrogen balance, the development of hypoalbuminemia, and infection due to the loss of immunoglobulin gamma (IgG).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Size selectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As illustrated in figure 3, the GBM is",
"    <strong>",
"     size",
"    </strong>",
"    and",
"    <strong>",
"     charge",
"    </strong>",
"    selective, as smaller and cationic molecules are more likely to be filtered. Both the GBM and the slit diaphragms between the foot processes of the epithelial cell contribute to size-selectivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The size limitation in the GBM represents functional pores in the spaces between the tightly packed cords of type IV collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the cellular components of the glomerular capillary wall are also important determinants of glomerular permeability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/13\">",
"     13",
"    </a>",
"    ]. This is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Macromolecules that pass through the GBM often accumulate below the slit diaphragms rather than passing into the urinary space.",
"     </li>",
"     <li>",
"      In vitro studies of isolated GBM indicate that the GBM is much more permeable to macromolecules than the intact glomerulus; the net effect is that the glomerular cells may be responsible for as much as 90 percent of the barrier to filtration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased protein filtration in glomerular diseases may primarily occur in areas of focal foot process detachment [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific proteins have been identified that play an important role in glomerular morphology and function. Podocalyxin is an anionic protein that lines the sides of the epithelial cell foot processes and is probably responsible, by electrostatic repulsion, for maintaining the separation of adjacent foot processes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/16\">",
"     16",
"    </a>",
"    ]. Mice that lack podocalyxin fail to form foot processes and slit diaphragms, have tight and adherens junctions in the epithelial cells, and are anuric presumably due to a lack of glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/17\">",
"     17",
"    </a>",
"    ]. On the other hand, a mutation in the gene for nephrin, a protein specifically located at the slit diaphragm, results in congenital nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the pores in the glomerular capillary wall are relatively small (mean radius about 42 &Aring;)&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/19\">",
"     19",
"    </a>",
"    ]: they partially restrict the filtration of albumin (mean radius 36 &Aring;), but allow the passage of smaller solutes and water [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/20\">",
"     20",
"    </a>",
"    ]. The endothelial cells, in comparison, do not contribute to size-selectivity, since the endothelial fenestrae are relatively wide open and do not begin to restrict the passage of neutral macromolecules until their radius is larger than 375 &Aring; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/21\">",
"     21",
"    </a>",
"    ]. These cells do, however, contribute to charge selectivity.",
"   </p>",
"   <p>",
"    &dagger;The data in Figure 3 used dextrans of different sizes. However, dextrans are long and pliable and may underestimate the impermeability to round macromolecules such as albumin. Studies using ficoll, which behaves as an ideal solid sphere, have estimated the pore radius to be 42 &Aring; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is also a much less numerous second population (less than 0.5 percent) of larger pores that permit the passage of macromolecules (including IgG) as large as 70 &Aring; [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/20\">",
"     20",
"    </a>",
"    ]. In normal subjects, however, only a very small amount of filtrate passes through these pores.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Charge selectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular charge is a second major determinant of filtration across the GBM [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/10,11,22\">",
"     10,11,22",
"    </a>",
"    ]. As illustrated in figure 3, cationic and neutral dextrans are filtered to a greater degree than anionic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sulfates of similar molecular sizes. This inhibitory effect of charge is due in part to electrostatic repulsion by anionic sites both in the endothelial fenestrae and in the GBM. The negative charge is primarily composed of heparan sulfate proteoglycans&dagger; (which are produced by the glomerular epithelial and endothelial cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/2,23\">",
"     2,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Albumin is a polyanion in the physiologic pH range. As with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sulfate, albumin filtration is only about 5 percent that of neutral dextran of the same molecular radius. Thus, charge as well as size limits the filtration of albumin. However, the importance of charge selectivity may not be as great as previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     Dextran",
"    </a>",
"    infusions have also been used in humans both to assess normal function and to determine the mechanism of the increase in protein excretion that typically occurs in glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/22,26\">",
"     22,26",
"    </a>",
"    ]. As illustrated in figure 4, for example, there is an increased number of larger pores as evidenced by a selective elevation in the clearance of neutral dextrans that are larger than 52 &Aring; in diameter (",
"    <a class=\"graphic graphic_figure graphicRef76597 \" href=\"UTD.htm?10/9/10399\">",
"     figure 4",
"    </a>",
"    ). Tunnels and cavities in the glomerular basement membrane appear to the pathways for protein leakage [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of loss of size selectivity is enhanced excretion of IgG (radius about 55 &Aring;) as well as albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/28\">",
"     28",
"    </a>",
"    ]. This pattern has been demonstrated in most glomerular diseases, including membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, and diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/22,28,29\">",
"     22,28,29",
"    </a>",
"    ]. In these conditions, however, the size defect can account for all of the increase in albumin excretion in only about one-half of cases, suggesting a concurrent defect in charge-selectivity which may be most prominent in minimal change disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Figure 4 also illustrates an important clinical difference between the filtration of larger proteins and that of smaller solutes and water (",
"    <a class=\"graphic graphic_figure graphicRef76597 \" href=\"UTD.htm?10/9/10399\">",
"     figure 4",
"    </a>",
"    ). The reduced clearance of smaller molecules in most proteinuric states reflects a decrease in surface area (due to fewer functioning pores) induced by the glomerular disease. At the same time, there is increased clearance of large proteins due to an enhanced number of larger pores (which still represent a very small fraction of the total number of pores) and perhaps partial loss of the charge barrier (which does not affect the filtration of smaller molecules).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     OTHER FUNCTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glomerular cells also have synthetic, phagocytic, and endocrine functions. The epithelial cells, for example, are thought to be responsible for the synthesis of the GBM and for the removal of circulating macromolecules that able to pass through the GBM and enter the subepithelial space [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/2,30\">",
"     2,30",
"    </a>",
"    ]. The endothelial cells, on the other hand, regulate vasomotor tone, in part via the release of prostacyclin, endothelin, and nitric oxide. They may also play an important role in inflammatory disorders involving the glomerulus by expressing adhesion molecules that promote the accumulation of inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mesangium, in comparison, is composed of two different types of cells. One is the mesangial cell, which has microfilaments similar to smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. After glomerular injury or depopulation of resident mesangial cells, new mesangial cells may originate from cells that normally reside in the juxtaglomerular apparatus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/34\">",
"     34",
"    </a>",
"    ]. These cells do not appear to be macrophages or smooth muscle or endothelial cells, or to excrete renin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=see_link\">",
"     \"Chapter 2D: Regulation of GFR and renal plasma flow\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intrinsic mesangial cells can respond to angiotensin II (which is locally produced by the endothelial cells in the afferent arteriole) and can synthesize prostaglandins, both of which play an important role in the regulation of glomerular hemodynamics (see below and Chap. 6) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/35\">",
"     35",
"    </a>",
"    ]. These cells also may be involved in immune-mediated glomerular diseases. They can both release a number of cytokines (including interleukin-1, interleukin-6, chemokines, and epidermal growth factor) and proliferate in response to cytokines (such as platelet-derived growth factor and epidermal growth factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/32,36,37\">",
"     32,36,37",
"    </a>",
"    ]. These actions can contribute to the hypercellularity, mesangial matrix expansion, and glomerular injury that are often seen in these disorders.",
"   </p>",
"   <p>",
"    The second cell type in the mesangium consists of circulating macrophages and monocytes that move into and out of the mesangium. These cells may have a primary phagocytic function, removing those macromolecules that enter the capillary wall but are unable to cross the basement membrane and move into the urinary space; they may also contribute to local inflammation in immune-mediated glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14518/abstract/38\">",
"     38",
"    </a>",
"    ]. Macromolecule entry into and subsequent removal from the mesangium can occur because most of the mesangium is separated from the capillary lumen only by the relatively permeable fenestrated endothelium, not by basement membrane (",
"    <a class=\"graphic graphic_figure graphicRef58117 \" href=\"UTD.htm?12/39/12913\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/1\">",
"      Beeuwkes R 3rd, Bonventre JV. Tubular organization and vascular-tubular relations in the dog kidney. Am J Physiol 1975; 229:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/2\">",
"      Abrahamson DR. Structure and development of the glomerular capillary wall and basement membrane. Am J Physiol 1987; 253:F783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/3\">",
"      Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol 2000; 11:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/4\">",
"      Weber M. Basement membrane proteins. Kidney Int 1992; 41:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/5\">",
"      Natori Y, O'Meara YM, Manning EC, et al. Production and polarized secretion of basement membrane components by glomerular epithelial cells. Am J Physiol 1992; 262:F131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/6\">",
"      Groffen AJ, Veerkamp JH, Monnens LA, van den Heuvel LP. Recent insights into the structure and functions of heparan sulfate proteoglycans in the human glomerular basement membrane. Nephrol Dial Transplant 1999; 14:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/7\">",
"      Kashtan CE. Alport syndrome and thin glomerular basement membrane disease. J Am Soc Nephrol 1998; 9:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/8\">",
"      Harvey SJ, Zheng K, Sado Y, et al. Role of distinct type IV collagen networks in glomerular development and function. Kidney Int 1998; 54:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/9\">",
"      Ding J, Stitzel J, Berry P, et al. Autosomal recessive Alport syndrome: mutation in the COL4A3 gene in a woman with Alport syndrome and posttransplant antiglomerular basement membrane nephritis. J Am Soc Nephrol 1995; 5:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/10\">",
"      Brenner BM, Hostetter TH, Humes HD. Molecular basis of proteinuria of glomerular origin. N Engl J Med 1978; 298:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/11\">",
"      Kanwar YS, Liu ZZ, Kashihara N, Wallner EI. Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 1991; 11:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/12\">",
"      Fujigaki Y, Nagase M, Kobayasi S, et al. Intra-GBM site of the functional filtration barrier for endogenous proteins in rats. Kidney Int 1993; 43:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/13\">",
"      Blantz RC, Gabbai FB, Peterson O, et al. Water and protein permeability is regulated by the glomerular epithelial slit diaphragm. J Am Soc Nephrol 1994; 4:1957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/14\">",
"      Daniels BS, Deen WM, Mayer G, et al. Glomerular permeability barrier in the rat. Functional assessment by in vitro methods. J Clin Invest 1993; 92:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/15\">",
"      Kerjaschki D. Dysfunctions of cell biological mechanisms of visceral epithelial cell (podocytes) in glomerular diseases. Kidney Int 1994; 45:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/16\">",
"      Sawada H, Stukenbrok H, Kerjaschki D, Farquhar MG. Epithelial polyanion (podocalyxin) is found on the sides but not the soles of the foot processes of the glomerular epithelium. Am J Pathol 1986; 125:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/17\">",
"      Doyonnas R, Kershaw DB, Duhme C, et al. Anuria, omphalocele, and perinatal lethality in mice lacking the CD34-related protein podocalyxin. J Exp Med 2001; 194:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/18\">",
"      Ruotsalainen V, Ljungberg P, Wartiovaara J, et al. Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci U S A 1999; 96:7962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/19\">",
"      Oliver JD III, Anderson S, Troy JL, et al. Determination of glomerular size-selectivity in the normal rat with ficoll. J Am Soc Nephrol 1992; 3:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/20\">",
"      Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: application to normal and nephrotic humans. Am J Physiol 1985; 249:F374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/21\">",
"      Latta H. An approach to the structure and function of the glomerular mesangium. J Am Soc Nephrol 1992; 2:S65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/22\">",
"      Scandling JD, Black VM, Deen WM, Myers BD. Glomerular permselectivity in healthy and nephrotic humans. Adv Nephrol 1992; 21:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/23\">",
"      Groggel GC, Stevenson J, Hovingh P, et al. Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int 1988; 33:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/24\">",
"      Comper WD, Glasgow EF. Charge selectivity in kidney ultrafiltration. Kidney Int 1995; 47:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/25\">",
"      Osicka TM, Comper WD. Glomerular charge selectivity for anionic and neutral horseradish peroxidase. Kidney Int 1995; 47:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/26\">",
"      Guasch A, Deen WM, Myers BD. Charge selectivity of the glomerular filtration barrier in healthy and nephrotic humans. J Clin Invest 1993; 92:2274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/27\">",
"      Ota Z, Shikata K, Ota K. Nephrotic tunnels in glomerular basement membrane as revealed by a new electron microscopic method. J Am Soc Nephrol 1994; 4:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/28\">",
"      Shemesh O, Ross JC, Deen WM, et al. Nature of the glomerular capillary injury in human membranous glomerulopathy. J Clin Invest 1986; 77:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/29\">",
"      Golbetz H, Black V, Shemesh O, Myers BD. Mechanism of the antiproteinuric effect of indomethacin in nephrotic humans. Am J Physiol 1989; 256:F44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/30\">",
"      Sharon Z, Schwartz MM, Pauli BU, Lewis EJ. Kinetics of glomerular visceral epithelial cell phagocytosis. Kidney Int 1978; 14:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/31\">",
"      Savage CO. The biology of the glomerulus: endothelial cells. Kidney Int 1994; 45:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/32\">",
"      Davies M. The mesangial cell: a tissue culture view. Kidney Int 1994; 45:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/33\">",
"      Ishino T, Kobayashi R, Wakui H, et al. Biochemical characterization of contractile proteins of rat cultured mesangial cells. Kidney Int 1991; 39:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/34\">",
"      Hugo C, Shankland SJ, Bowen-Pope DF, et al. Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. J Clin Invest 1997; 100:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/35\">",
"      Striker GE, Striker LJ. Glomerular cell culture. Lab Invest 1985; 53:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/36\">",
"      Kusner DJ, Luebbers EL, Nowinski RJ, et al. Cytokine- and LPS-induced synthesis of interleukin-8 from human mesangial cells. Kidney Int 1991; 39:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/37\">",
"      Moriyama T, Fujibayashi M, Fujiwara Y, et al. Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995; 6:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14518/abstract/38\">",
"      Schreiner GF. The mesangial phagocyte and its regulation of contractile cell biology. J Am Soc Nephrol 1992; 2:S74.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7276 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14518=[""].join("\n");
var outline_f14_11_14518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOMERULAR ANATOMY AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Filtration barrier and protein excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Size selectivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Charge selectivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      OTHER FUNCTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7276\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7276|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/63/13296\" title=\"figure 1\">",
"      Renal circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/39/12913\" title=\"figure 2\">",
"      Glomerular anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/62/7151\" title=\"figure 3\">",
"      Glomerular permeability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/9/10399\" title=\"figure 4\">",
"      Protein filtration in FGS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10985?source=related_link\">",
"      Chapter 2D: Regulation of GFR and renal plasma flow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24617?source=related_link\">",
"      Chapter 3A: Cell model for proximal transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14519="Nutritional status and protein intake in continuous peritoneal dialysis";
var content_f14_11_14519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nutritional status and protein intake in continuous peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14519/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14519/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14519/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14519/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/11/14519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical data using surrogate markers of nutritional status such as serum albumin levels suggest that moderate to severe malnutrition is common in patients undergoing maintenance dialysis. This complication is of concern, since inadequate nutrition is an important determinant of patient mortality. As an example, when surrogate markers of malnutrition (serum albumin or creatinine concentrations) are used as predictors of mortality risk, mortality is increased in a dose-dependent fashion with either hypoalbuminemia or a low plasma creatinine concentration predicting an increased relative risk of death (",
"    <a class=\"graphic graphic_figure graphicRef60944 \" href=\"UTD.htm?19/49/20253\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Hypoalbuminemia may not always result from malnutrition, although the association with mortality still exists. It is now well recognized that there are other causes of a low serum albumin, such as chronic inflammation and excessive peritoneal albumin losses during dialysis as is commonly seen in patients who have rapid peritoneal transport characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/1\">",
"     1",
"    </a>",
"    ]. One possible mechanism for this increased relative risk of death may be the association between inflammation, hypoalbuminemia and atherosclerosis. Investigators have shown a strong relationship between malnutrition, elevated C reactive protein (CRP) levels, hypoalbuminemia and atherosclerosis, termed the malnutrition, inflammation and atherosclerosis (MIA) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link&amp;anchor=H17#H17\">",
"     \"Inflammation in renal insufficiency\", section on 'Malnutrition may lead to inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These general issues are discussed in detail elsewhere. This topic will review those concerns that are specifically related to the patient treated with continuous peritoneal dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link&amp;anchor=H20#H20\">",
"     \"Patient survival and maintenance dialysis\", section on 'Malnutrition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Using the plasma albumin concentration, creatinine production, or other nutritional parameters, it has been estimated that 40 to 66 percent of peritoneal dialysis patients in the United States are malnourished [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. The potential importance of nutrition was illustrated in a study that compared laboratory values in patients who survived one year on continuous ambulatory peritoneal dialysis (CAPD) to those who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/7\">",
"     7",
"    </a>",
"    ]. The survivors had a higher plasma albumin concentration (3.7 versus 3.4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [37 versus 34",
"    <span class=\"nowrap\">",
"     g/L])",
"    </span>",
"    and a higher plasma creatinine concentration (10.7 versus 9.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [946 versus 866",
"    <span class=\"nowrap\">",
"     &micro;mol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    The prognostic importance of the plasma albumin concentration in PD patients was also shown in the final report of a prospective, multicenter evaluation of dialysis dose and nutritional status of peritoneal dialysis patients in Canada and the United States (CANUSA) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/11\">",
"     11",
"    </a>",
"    ]. Each 1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    increase in the plasma albumin concentration decreased the relative risk of death by 6 percent.",
"   </p>",
"   <p>",
"    A related issue is the nutritional status upon initiation of continuous peritoneal dialysis. Increasing evidence suggests that survival is lower and nutritional status remains poor if dialysis is initiated late in the course of chronic renal failure, particularly among those who are malnourished and have minimal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/12\">",
"     12",
"    </a>",
"    ]. When baseline nutritional status of 283 Indian CAPD patients was evaluated using anthropometry, dietary diary, subjective global assessment, and serum albumin, the majority of predialysis patients were found to be malnourished, and these parameters tended to improve after the initiation of dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/13\">",
"     13",
"    </a>",
"    ]. Hence, many national guideline committees have recommended maintaining normal nutrition while on dialysis and prior to dialysis when patients have advance chronic kidney disease. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for PD adequacy, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=see_link\">",
"     \"Indications for initiation of dialysis in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These findings illustrate the potential importance of monitoring the nutritional status in patients on continuous peritoneal dialysis. The hope is that early identification of malnutrition and optimal use of diet, the dialysis dose, and perhaps supplements (both oral or IP) will lead to an improvement in nutritional status and patient outcome. In addition to inadequate dialysis, there are several other factors that can contribute to the development of malnutrition that are relatively specific to peritoneal dialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Losses of protein and amino acids into the peritoneal dialysate are often as high as 8",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      tend to be highest in patients who are rapid transporters, and can rise much higher during episodes of peritonitis.",
"     </li>",
"     <li>",
"      Dialysate in the abdomen imparts a feeling of fullness that dulls the appetite.",
"     </li>",
"     <li>",
"      Slow gastric emptying, which also causes a feeling of fullness, is common because many CAPD patients are diabetic.",
"     </li>",
"     <li>",
"      Hyperglycemia, which can be induced by the absorption of glucose from the dialysate, can cause anorexia.",
"     </li>",
"     <li>",
"      Continued glucose absorption from the peritoneum may suppress appetite.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MARKERS OF NUTRITIONAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of methods can be used to assess nutritional status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=see_link\">",
"     \"Assessment of nutritional status in end-stage renal disease\"",
"    </a>",
"    .) The plasma albumin concentration, for example, is thought to reflect body visceral protein stores. It takes many months of sustained malnutrition for these stores to become depleted. As a result, the plasma albumin concentration should be monitored monthly in maintenance dialysis patients.",
"   </p>",
"   <p>",
"    Estimation of lean body mass (LBM) is also useful, but the ability to measure this parameter has not been widely available. One report, however, suggests that LBM can be estimated relatively simply by measuring creatinine kinetics with 24-hour dialysate and urine collections, a standard procedure for most units that are monitoring dialysis dose [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/8\">",
"     8",
"    </a>",
"    ]. In the steady state, creatinine production equals creatinine excretion. Therefore, creatinine production is equal to:",
"   </p>",
"   <p>",
"    &nbsp;Creatinine production,",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    &nbsp; = &nbsp; excretion &nbsp;+ &nbsp;metabolic degradation",
"   </p>",
"   <p>",
"    Creatinine excretion can be calculated from:",
"   </p>",
"   <p>",
"    &nbsp;Creatinine excretion,",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    &nbsp; = &nbsp; (Vu &nbsp;x &nbsp;Cu) &nbsp; + &nbsp; (Vd &nbsp;x &nbsp;Cd)",
"   </p>",
"   <p>",
"    where V and C represent volume and creatinine concentration in the urine (u) and dialysate (d). Creatinine degradation can be estimated from the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Creatinine degradation,",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    &nbsp; = &nbsp; 0.38 &nbsp; x &nbsp; Pcr",
"    <span class=\"nowrap\">",
"     (mg/dL)",
"    </span>",
"    &nbsp; x &nbsp;body weight (kg)",
"   </p>",
"   <p>",
"    where Pcr is the plasma creatinine concentration. Using these two formulas to estimate creatinine production in",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    the LBM can be estimated from:",
"   </p>",
"   <p>",
"    &nbsp;LBM, kg &nbsp; = &nbsp; (0.029 &nbsp;x &nbsp;production) &nbsp; + &nbsp; 7.38",
"   </p>",
"   <p>",
"    The results obtained with this method were found to be statistically as accurate as those using more sophisticated total body water techniques. Although the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for adequacy of PD no longer recommend using creatinine kinetics as the recommended surrogate for small solute dose, the guidelines note that one may use sequential 24-hour collections of dialysate and urine to calculate creatinine production and estimate changes in lean body mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Protein intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another predictor of the patient's underlying nutritional status is daily dietary protein intake (DPI). These measurements are hard to obtain directly because of the need for extensive food record keeping by the patient and for dietitians specifically trained in evaluating food intake histories. Fortunately, urea kinetic modeling techniques, commonly used to determine dialysis dose, can also be utilized to calculate the protein equivalent nitrogen appearance rate (PNA), usually referred to as the protein catabolic rate (PCR). The PCR in hemodialysis is estimated from urea appearance as determined by the interdialytic rise in BUN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=see_link\">",
"     \"Protein catabolic rate in maintenance dialysis\"",
"    </a>",
"    .) However, this approach cannot be applied to continuous peritoneal dialysis, since the BUN is relatively constant. In this setting, urea appearance (a presumed reflection of protein intake in a noncatabolic patient) is estimated from urea and amino acid losses in the dialysate and urine.",
"   </p>",
"   <p>",
"    Several equations have been used to estimate the PCR in continuous peritoneal dialysis; at present, we use the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;PCR &nbsp; = &nbsp; 6.25 &nbsp;x &nbsp;(Urea appearance &nbsp;+ &nbsp;1.81 &nbsp;+ &nbsp;[0.031 &nbsp;x &nbsp;lean body weight, kg])",
"   </p>",
"   <p>",
"    The last term in this formula reflects the contribution of nonurea protein metabolism. Urea appearance can be estimated from 24-hour dialysate and urine collections:",
"   </p>",
"   <p>",
"    &nbsp;Urea appearance,",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    &nbsp; = &nbsp; (Vu &nbsp;x &nbsp;Cu) &nbsp; + &nbsp; (Vd &nbsp;x &nbsp;Cd)",
"   </p>",
"   <p>",
"    where V and C represent volume and urea concentration in the urine (u) and dialysate (d).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of dialysis dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PCR, which reflects dietary protein intake, is influenced by the degree of dialysis or solute removal. Thus, an increase in dialysis dose from an inappropriately low level may enhance protein intake via an improvement in appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. This relationship was demonstrated in a small group of hemodialysis patients in whom the intensity of dialysis was increased by enhancing dialysis time, blood flow,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    membrane surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/15\">",
"     15",
"    </a>",
"    ]. As the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    rose from 0.82 to 1.32 over a three-month period, there was a concurrent elevation in PCR from 0.81 to 1.02",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day. A second group in which the dialysis regimen was unchanged had no increase in either",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or PCR.",
"   </p>",
"   <p>",
"    The relationship between nutritional intake and dialysis dose among patients undergoing peritoneal dialysis was addressed in the Canada-USA (CANUSA) peritoneal dialysis study group trial in which 680 patients were followed for approximately two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/18\">",
"     18",
"    </a>",
"    ]. Due to the controversy surrounding the possible mathematical relationship between PCR and",
"    <span class=\"nowrap\">",
"     Kt/V,",
"    </span>",
"    the correlation between changes in peritoneal dialysis adequacy and alterations in nutritional intake was evaluated using numerous parameters of intake, including serum albumin, subjective global assessment (SGA), lean body mass (LBM), protein catabolic rate (PCR), and normalized protein catabolic rate (nPCR). For the first six months, a significantly positive correlation was observed between increased peritoneal dialysis and improvement in all parameters of nutrition except for the serum albumin concentration. In addition, at 6 to 18 months of follow-up, a decrease in total clearance due to the loss of residual renal function was associated with a nonsignificant trend toward reduced LBM and SGA, and significant declines in PCR and nPCR.",
"   </p>",
"   <p>",
"    Improved nutritional intake has been noted with increased dialysis dose. In another study, improved body weight was observed with more frequent daily hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear what level of DPI (as estimated from PCR) is needed to maintain positive nitrogen balance in patients treated with peritoneal dialysis. Early balance studies suggested that a minimal DPI of 1.2",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day was needed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, some patients tend to ingest 0.9 to 1.0",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day without any obvious signs of malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. If it is assumed that a minimal DPI of at least 1.0 g of",
"    <span class=\"nowrap\">",
"     protein/kg",
"    </span>",
"    per day is required in the average patient, then the \"minimal\" target total, solute clearance (in terms of",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or CrCl) can be extrapolated from plots of PCR versus solute clearance as measured from urea or creatinine kinetics (",
"    <a class=\"graphic graphic_figure graphicRef81842 \" href=\"UTD.htm?7/55/8062\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The minimal target doses obtained in this manner are similar to those obtained from observational studies based upon patient outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/24\">",
"     24",
"    </a>",
"    ]. Minimal target doses are discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .) It is important to note that, although there are observational studies that have correlated risk of death with surrogates of nutritional status, there are no published prospective randomized trials that kept dose of PD constant and compared baseline care to a nutritional intervention to demonstrate an improvement in outcome.",
"   </p>",
"   <p>",
"    Therefore, recommendations are based on indirect evidence and opinion. With respect to dietary instruction, we currently recommend that, during training, patients eat 1.2 to 1.3 g of",
"    <span class=\"nowrap\">",
"     protein/kg",
"    </span>",
"    per day. Data obtained from NHANES nomograms should be used to estimate standard body weight. Use of these nomograms is important because different patients have different metabolic rates and body weights that may be markedly different from normal for their age, sex, height, and body frame. Target protein intake should not be related to LBM, which is defined as the fat-free mass. Estimated LBM will be increased in edematous individuals and reduced in volume depleted patients, even though there may be no change in muscle mass. This is consistent with the recommendations from the 2005 European Best Practice Guidelines for peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/26\">",
"     26",
"    </a>",
"    ]. Dietary instructions should be reviewed quarterly or more often, if clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the patient's routine monthly visit, we monitor the plasma levels of urea nitrogen, creatinine, and albumin. The aim is to maintain a normal plasma albumin concentration (greater than 4.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or 40",
"    <span class=\"nowrap\">",
"     g/L).",
"    </span>",
"    Dietary instructions should be reviewed quarterly or more often, if clinically indicated.",
"   </p>",
"   <p>",
"    In stable patients, we measure small solute clearance per",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines and monitor overnight (CAPD) or daytime (APD) drain volumes to estimate peritoneal transport. We obtain peritoneal membrane function studies yearly (although the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines only recommend them at baseline and when clinically indicated). Total solute clearance is best achieved using data obtained from 24-hour collections of dialysate and urine; values estimated from kinetic modeling programs or from a four-hour dwell can be inaccurate [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .) The dialysate and urine collections also permit calculation of the PCR and creatinine production according to the above formulas. Peritoneal membrane function is determined from standard peritoneal equilibration testing (PET). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any patient with a low plasma albumin concentration should be closely evaluated for the possibility of underlying malnutrition, particularly if the albumin level, PCR, or LBM has declined over time. It is important in this setting to exclude or treat any overt or occult comorbid disease that might be impairing nutritional status. One also must rule out chronic inflammatory states and consider rapid peritoneal transport with associated peritoneal albumin losses as a cause. If no such disease is present, then the dialysis dose should be increased. This is most easily achieved by increasing the dwell volume (eg, from 2 to 2.5 L) or by increasing the number of exchanges per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link\">",
"     \"Adequacy of peritoneal dialysis\"",
"    </a>",
"    .) One circumstance in which underdialysis gradually occurs is in patients who lose their residual renal function and its contribution to the excretion of uremic toxins. Problems with solute clearance across the peritoneal membrane can also occur, often manifested by a rise in the BUN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The European Best Practices Guidelines also suggest that monitoring include a subjective global assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dietary supplements may be required in patients with persistent malnutrition, despite a seemingly adequate dialysis dose. The approach to such patients is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another potential approach to patients with hypoalbuminemia (or other signs of malnutrition) but an adequate dialysis dose is the administration of supplemental protein feedings. Oral protein is the only modality currently available for outpatients. In addition, peritoneal dialysis fluids containing amino acids instead of glucose as the osmotic agent are now available. Long-term studies are pending, but initial observations suggest that use of these fluids can lead to an elevation in the plasma albumin concentration and improvement in other biochemical parameters of nutritional status. There are, however, some potential problems with this solution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis and treatment of malnutrition in maintenance dialysis\", section on 'Amino acid dialysate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Special situations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, there appears to be a dissociation between dialysis dose and the plasma albumin concentration. As an example, a patient may have hypoalbuminemia but a seemingly adequate dialysis prescription. Possible explanations for this problem include noncompliance, chronic inflammation, comorbidity, and rapid solute transport across the peritoneal membrane. Rapid transporters tend to lose more protein in the dialysate (promoting the development of hypoalbuminemia) and absorb more glucose from the dialysate than the average patient on CAPD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although not proven, these patients may need even higher dietary protein intakes to prevent negative nitrogen balance. In addition to the increase in protein losses, there is some evidence that excessive glucose absorption can suppress appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14519/abstract/31\">",
"     31",
"    </a>",
"    ]; this problem may be exacerbated by the frequent use of hypertonic exchanges to achieve adequate ultrafiltration. One possible, although unproven, therapy in these patients is to change from the long dwells associated with CAPD to a short dwell regimen (such as nightly peritoneal dialysis with a cycler).",
"   </p>",
"   <p>",
"    Rapid transporters can be identified by performing a standardized peritoneal equilibration test, which demonstrates a higher than average dialysate-to-plasma creatinine concentration of 0.8 or more at four hours (",
"    <a class=\"graphic graphic_figure graphicRef65815 \" href=\"UTD.htm?1/63/2047\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients have a different problem: the present dialysis dose (as estimated from",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    or creatinine clearance) is below target, but there is no evidence of malnutrition or uremic symptoms. KDOQI guidelines recommend that the total solute clearance be increased to above the minimal target of a",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    &gt;",
"    <span class=\"nowrap\">",
"     1.7/week",
"    </span>",
"    for such patients and that they be carefully monitored. The dialysis prescription should be further increased if there is a reduction in the plasma albumin concentration, PCR, or lean body mass.",
"   </p>",
"   <p>",
"    An alternative constellation of clinical findings may also occur: the patient appears malnourished and has a low serum concentration of albumin, but the",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    appears adequate and no additional disease process is apparent. This may be explained by the use of a progressively smaller V, resulting in an apparently normal",
"    <span class=\"nowrap\">",
"     Kt/V;",
"    </span>",
"    however, the absolute amount of cleared solute does not promote increased DPI and anabolism. In this clinical setting, the NKF-DOQI guidelines recommend increasing the target",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    by using the ratio of",
"    <span class=\"nowrap\">",
"     ideal/actual",
"    </span>",
"    body weight.",
"   </p>",
"   <p>",
"    Finally, patients may have a low albumin as part of a chronic inflammatory state. They typically have a low serum albumin, elevated ferritin level, and elevation of other markers of chronic inflammation, such as an elevated CRP and sedimentation rate. Their approach and treatment of this condition is outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=see_link\">",
"       \"Patient information: Dialysis and diet (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/1\">",
"      Heath, JG, Srac, S, Afzal, S. A high peritoneal large pore flux causes hypoalbuminemia and is a risk factor for death in peritoneal dialysis patients. Neph Dial Transpl 2005; 20:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/2\">",
"      Stenvinkel P, Heimb&uuml;rger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/3\">",
"      de Mutsert R, Grootendorst DC, Axelsson J, et al. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008; 23:2957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/4\">",
"      Marckmann P. Nutritional status of patients on hemodialysis and peritoneal dialysis. Clin Nephrol 1988; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/5\">",
"      Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/6\">",
"      Teehan BP, Schleifer CR, Brown JM, et al. Urea kinetic analysis and clinical outcome on CAPD. A five year longitudinal study. Adv Perit Dial 1990; 6:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/7\">",
"      Rocco MV, Jordan JR, Burkart JM. The efficacy number as a predictor of morbidity and mortality in peritoneal dialysis patients. J Am Soc Nephrol 1993; 4:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/8\">",
"      Keshaviah PR, Nolph KD, Moore HL, et al. Lean body mass estimation by creatinine kinetics. J Am Soc Nephrol 1994; 4:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/9\">",
"      Flanigan MJ, Bailie GR, Frankenfield DL, et al. 1996 Peritoneal Dialysis Core Indicators Study: report on nutritional indicators. Perit Dial Int 1998; 18:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/10\">",
"      2005 Annual Report: ESRD clinical performance measures project. Am J Kidney Dis 2006; 48(Suppl 2):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/11\">",
"      Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J Am Soc Nephrol 1996; 7:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/12\">",
"      Misra M, Nolph KD, Khanna R, et al. Retrospective evaluation of renal kt/V(urea) at the initiation of long-term peritoneal dialysis at the University of Missouri: relationships to longitudinal nutritional status on peritoneal dialysis. ASAIO J 2003; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/13\">",
"      Prasa, N, Gupta, A, Sinha, A, et al. Changes in nutritional status on follow up of an incident cohort of continuous ambulatory peritoneal dialysis patients. J Ren Nutri 2008; 18:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/14\">",
"      Keshaviah PR, Nolph KD. Protein catabolic rate calculations in CAPD patients. ASAIO Trans 1991; 37:M400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/15\">",
"      Lindsay RM, Spanner E, Heidenheim RP, et al. Which comes first, Kt/V or PCR--chicken or egg? Kidney Int Suppl 1992; 38:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/16\">",
"      Keshaviah P. Adequacy of CAPD: a quantitative approach. Kidney Int Suppl 1992; 38:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/17\">",
"      Kappas AM, Fatouros M, Siamopoulos K, et al. Phosphatidylcholine and intraperitoneal adhesions. Perit Dial Int 1993; 13 Suppl 2:S77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/18\">",
"      McCusker FX, Teehan BP, Thorpe KE, et al. How much peritoneal dialysis is required for the maintenance of a good nutritional state? Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Kidney Int Suppl 1996; 56:S56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/19\">",
"      Lindsay RM, Nesrallah G, Suri R, et al. Is more frequent hemodialysis beneficial and what is the evidence? Curr Opin Nephrol Hypertens 2004; 13:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/20\">",
"      Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982; 21:849.",
"     </a>",
"    </li>",
"    <li>",
"     Diamond, SM, Henrich, WL. Nutrition and peritoneal dialysis. In: Nutrition and the Kidney, Mitch, WE, Klahr, S (Eds), Little, Brown, Boston, 1988, p 198.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/22\">",
"      Bergstr&ouml;m J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int Suppl 1993; 40:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/23\">",
"      Nolph KD. What's new in peritoneal dialysis--an overview. Kidney Int Suppl 1992; 38:S148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/24\">",
"      Teehan, BP, Schleifer, CR, Brown, J. Urea kinetic modeling is an appropriate assessment of adequacy. Semin Dial 1992; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/25\">",
"      NKF-DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. V. Adequate dose of peritoneal dialysis. Am J Kidney Dis 2001; 37(Suppl 1):S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/26\">",
"      European Best Practice Guidelines for peritoneal dialysis. Nephrol Dial Transplant 2005; 20(Suppl 9):3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/27\">",
"      Burkart JM, Jordan JR, Rocco MV. Assessment of dialysis dose by measured clearance versus extrapolated data. Perit Dial Int 1993; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/28\">",
"      Nolph KD, Moore HL, Prowant B, et al. Continuous ambulatory peritoneal dialysis with a high flux membrane. ASAIO J 1993; 39:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/29\">",
"      Burkart, JM, Jordan, J, Rocco, MV. Cross sectional analysis of D/P creatinine ratios versus serum albumin values in NIPD patients. Perit Dial Int 1994; 14(Suppl 1):S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/30\">",
"      Nolph KD, Moore HL, Prowant B, et al. Cross sectional assessment of weekly urea and creatinine clearances and indices of nutrition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1993; 13:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14519/abstract/31\">",
"      Hylander B, Barkeling B, R&ouml;ssner S. Eating behavior in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Kidney Dis 1992; 20:592.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1855 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-42E0F5FCD1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14519=[""].join("\n");
var outline_f14_11_14519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MARKERS OF NUTRITIONAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Protein intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Special situations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1855\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1855|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/49/20253\" title=\"figure 1\">",
"      Risk of mortality among dial pts according to baseline albumin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/55/8062\" title=\"figure 2\">",
"      PCR and KtV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/63/2047\" title=\"figure 3\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15399?source=related_link\">",
"      Assessment of nutritional status in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4616?source=related_link\">",
"      Indications for initiation of dialysis in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9274?source=related_link\">",
"      Pathogenesis and treatment of malnutrition in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/2/18467?source=related_link\">",
"      Patient information: Dialysis and diet (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/277?source=related_link\">",
"      Protein catabolic rate in maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14520="Incidence and mortality of the premature infant";
var content_f14_11_14520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Incidence and mortality of the premature infant",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14520/contributors\">",
"     George T Mandy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14520/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14520/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14520/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/11/14520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prematurity is defined as a birth that occurs before 37 completed weeks (less than 259 days) of gestation. It is associated with approximately one-third of all infant deaths in the United States. Infants born at or before 25 weeks of gestation have the highest mortality rate (about 50 percent) and if they survive, are at the greatest risk for severe impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence and mortality rate of preterm birth will be reviewed here. The risk and pathogenesis of preterm birth and complications of prematurity are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birthweight (BW).",
"   </p>",
"   <p>",
"    One classification based upon BW includes the following categories (",
"    <a class=\"graphic graphic_table graphicRef57685 \" href=\"UTD.htm?1/8/1163\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW) &ndash; BW less than 2500 g",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW) &ndash; BW less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW) &ndash; BW less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This classification based upon BW is primarily used in this review.",
"   </p>",
"   <p>",
"    BW percentiles have been established for the appropriate GA (",
"    <a class=\"graphic graphic_table graphicRef81379 \" href=\"UTD.htm?10/59/11197\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Prematurity is also defined by gestational age (GA) as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Late preterm infants &ndash; GA between 34 weeks and 36 weeks and 6 days",
"     </li>",
"     <li>",
"      Very premature infants (VPT) &ndash; GA at or below 32 weeks",
"     </li>",
"     <li>",
"      Extremely premature infants (EPT) &ndash; GA at or below 25 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, the preterm birth rate is estimated to be about 11 percent (range 5 percent in parts of Europe to 18 percent in parts of Africa), and about 15 million children are born preterm each year (range 12 to 18 million) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Of these preterm births, 84 percent occurred at 32 to 36 weeks gestational age (GA), 10 percent occurred at 28 to &lt;32 weeks GA, and 5 percent occurred at &lt;28 weeks GA.",
"   </p>",
"   <p>",
"    In the United States, approximately 550,000 premature infants are born each year. In 2011, about 11.7 percent of all live births were &lt;37 weeks GA and 2 percent &lt;32 weeks GA (",
"    <a class=\"graphic graphic_table graphicRef61972 \" href=\"UTD.htm?2/10/2220\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72127 \" href=\"UTD.htm?20/43/21182\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Low birth weight (LBW) infants accounted for 8.1 percent of live births in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, there has been a 21 percent rise in the overall proportion of preterm births since 1990, which peaked in 2006 with 12.8 percent of all live births born at a GA &lt;37 weeks, and has subsequently declined to 11.7 in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/4\">",
"     4",
"    </a>",
"    ]. In Norway, a population-based report of all live births in 1999 and 2000 reported an incidence of 0.5 percent of ELBW infants born between 22 and 27 weeks GA [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Multiple gestation and ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, a major reason for the increased incidence of premature birth is the higher rate of multiple gestations, in part due to assisted reproductive technology (ART). Infants of multiple gestation are prone to delivery early; half of all twin births and &gt;90 percent of triplets are born premature. In 2011, the rate of twin births and higher-order multiple births were 33.1 and 0.1 per 1000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=see_link\">",
"     \"Neonatal outcome, complications, and management of multiple births\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=see_link\">",
"     \"Strategies to control the rate of high order multiple gestation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of premature births varies among ethnic groups. In 2009, the percentages of live births in the United States that were preterm by ethnicity were 16.8, 11.7, and 10.5 per 1000 live births in non-Hispanic blacks, Hispanics, and non-Hispanic whites, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/4\">",
"     4",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef59601 \" href=\"UTD.htm?16/13/16607\">",
"     figure 2",
"    </a>",
"    ). A higher rate of low birth weight infants in minority populations also occurs in England, with reported percentages of low birth weight live births of 11.5, 9.4, and 5.4 percent in Asian, black, and white mothers, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS FOR PRETERM BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of preterm deliveries occur spontaneously as a result of preterm labor (50 percent) or preterm rupture of membranes (30 percent); intervention for maternal or fetal problems account for the remaining 20 percent (",
"    <a class=\"graphic graphic_table graphicRef74561 \" href=\"UTD.htm?7/40/7819\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The four primary causes that lead to preterm labor and delivery are as follow and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"     \"Pathogenesis of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Activation of the maternal or fetal hypothalamic-pituitary-adrenal axis",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"     <li>",
"      Decidual hemorrhage",
"     </li>",
"     <li>",
"      Pathological uterine distention",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk factors for preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with preterm labor and delivery include the following sociodemographic and obstetric factors, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal reproductive factors such as history of preterm birth and maternal age. A U-shaped relationship exists between maternal age and the frequency of preterm birth. Women under 16 and those above 35 have a 2 to 4 percent higher rate of preterm birth compared with those between 21 and 24 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/8\">",
"       8",
"      </a>",
"      ]. Among non-Hispanic black women, the upper age with an increased risk of preterm delivery is lower with preterm birth rates increasing at 27 to 29 years of age compared with 33 to 35 years of age for non-Hispanic white women.",
"     </li>",
"     <li>",
"      Maternal disorders such as infection, anemia, hypertension,",
"      <span class=\"nowrap\">",
"       preeclampsia/eclampsia,",
"      </span>",
"      cardiovascular and pulmonary disorders, and diabetes.",
"     </li>",
"     <li>",
"      Maternal lifestyle issues such as physical activity, history of substance abuse or smoking, diet, weight, and stress.",
"     </li>",
"     <li>",
"      Cervical, uterine, and placental factors such as short cervix, cervical surgery, uterine malformations, vaginal bleeding, and placenta previa or abruption.",
"     </li>",
"     <li>",
"      Multiple gestation",
"     </li>",
"     <li>",
"      Fetal factors such as presence of congenital anomalies, growth restriction, fetal infections, and fetal distress.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low birth weight and prematurity are major contributors to infant mortality. In the yearly analysis from the National Center for Health Statistics that links all birth and infant deaths (through the first year of age) in the United States, birth weight less than 2000 g was associated with 61 percent of infant deaths in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that cause variation in premature mortality rates include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Degree of prematurity &ndash; Mortality rises with increasing immaturity (ie, decreasing birthweight and gestational age)",
"     </li>",
"     <li>",
"      Maternal ethnicity",
"     </li>",
"     <li>",
"      Level of neonatal care",
"     </li>",
"     <li>",
"      Congenital anomalies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gestational age and birth weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates amongst premature infants correlate with birthweight and gestational age with decreases in both associated with poorer survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Thus infants born with the lowest gestational age and birthweight have the largest impact on infant mortality because they have the greatest risk of death. As an example, although infants who weigh less than 1000 g account for only 0.8 percent of births in the United States, they accounted for 55 percent of all infants deaths in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2007, infant mortality rates per 1000 live births based upon birth weight were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2500 g &ndash; 2.3",
"     </li>",
"     <li>",
"      &lt;2500 g &ndash; 56",
"     </li>",
"     <li>",
"      &lt;1500 g &ndash; 241",
"     </li>",
"     <li>",
"      &lt;500 g &ndash; 850",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar relationship with increasing mortality rates per 1000 live births and decreasing gestational age (GA) was also noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      37 to 41 weeks GA &ndash; 2.43",
"     </li>",
"     <li>",
"      34 to 36 weeks GA &ndash; 7.4",
"     </li>",
"     <li>",
"      32 to 33 weeks GA &ndash; 16",
"     </li>",
"     <li>",
"      Less than 32 weeks &ndash; 178",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mortality data for infants born at or below 25 weeks gestation who are at the limit of viability are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .) Overall, more than two-thirds of infant deaths occur during the neonatal period defined as less than 28 days of age. The risk of dying within this neonatal period increases with decreasing gestational age. In addition, lower birth weights due to fetal growth restriction increase mortality at a given gestational age in premature infants born at or below 31 weeks gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link&amp;anchor=H19#H19\">",
"     \"Small for gestational age infant\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Extremely preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although infants born at or before 25 weeks of gestation have the highest mortality rate, about 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], it appears that the survival rate of infants between 24 and 26 weeks gestation has improved with advances in neonatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Trends over time'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Risk factors for death or severe neurosensory impairment in extremely low birth weight (ELBW) infants (birth weight less than 1000 g) include bronchopulmonary dysplasia, brain injury, severe retinopathy of prematurity, and infection (eg, meningitis, sepsis, and necrotizing enterocolitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, infants who received cardiopulmonary resuscitation (CPR) in the delivery room have increased risk of mortality or severe neurodevelopment impairment in survivors than those who did not receive CPR [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/15\">",
"     15",
"    </a>",
"    ]. CPR recipients were more likely to have lower birth weights and gestational age, and were sicker with higher rates of pneumothorax, grade III and IV intraventricular hemorrhage, and bronchopulmonary dysplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=see_link\">",
"     \"Short-term complications of the premature infant\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=see_link\">",
"     \"Long-term neurodevelopmental outcome of premature infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Late preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late preterm infants (born between 34 weeks, and 36 weeks and 6 days gestation) are an \"at risk population\" with a three- to fivefold greater risk of mortality than term infants. The mortality of later preterm infants is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=see_link&amp;anchor=H18#H18\">",
"     \"Late preterm infants\", section on 'Mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6163667\">",
"    <span class=\"h2\">",
"     Gender",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male preterm infants have a higher mortality rate than female infants (odds ratio [OR] 1.29, 95% CI 1.4-1.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/16\">",
"     16",
"    </a>",
"    ] . Adverse neurologic outcome (defined as moderate to severe functional disability at 2 to 3 years of age) is also greater in male infants (OR 1.9, 95% CI 1.4-2.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates of premature infants vary among ethnic groups as demonstrated by infant mortality data from the United States in 2004 (",
"    <a class=\"graphic graphic_figure graphicRef59601 \" href=\"UTD.htm?16/13/16607\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/17\">",
"     17",
"    </a>",
"    ]. The highest mortality rate is in black infants at any given gestational age or birthweight compared with other ethnic groups.",
"   </p>",
"   <p>",
"    For example, the infant mortality rates per 1000 live births for premature infants with birth weights &lt;1500 g (very low birth weight infants) based upon maternal ethnicity were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall &ndash; 244.5",
"     </li>",
"     <li>",
"      White &ndash; 231.9",
"     </li>",
"     <li>",
"      Black &ndash; 274",
"     </li>",
"     <li>",
"      Asian or Pacific Islander &ndash; 222.7",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar differences in infant mortality rate based upon gestational age were reported among ethnic groups. The infant mortality rates per 1000 live births for premature infants with gestational age &lt;32 weeks based upon maternal ethnicity were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall &ndash; 182.5",
"     </li>",
"     <li>",
"      White &ndash; 168.4",
"     </li>",
"     <li>",
"      Black &ndash; 216.2",
"     </li>",
"     <li>",
"      Asian or Pacific Islander &ndash; 173.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health care disparities may in part explain the higher mortality rate of black infants versus other ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Level of neonatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variation in neonatal care impacts on mortality rate and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in care over time with the introduction of new therapeutic interventions and changes in management.",
"     </li>",
"     <li>",
"      Delivery of care based upon hospital resources and experiences.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Trends over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in newborn intensive care, including the use of surfactant treatment and antenatal steroid therapy to prevent and treat neonatal respiratory distress syndrome, have resulted in decreased mortality rates of preterm infants, except in those who are at the limit of viability [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/12,19-23\">",
"     12,19-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H3#H3\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Evidence of short-term clinical efficacy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=see_link\">",
"     \"Prevention and treatment of respiratory distress syndrome in preterm infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"     \"Limit of viability\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was demonstrated by the improved survival rate for very low birth weight (VLBW) infants (birth weights between 500 and 1500 g) reported by the United States National Institute of Child Health and Human Development (NICHD) Neonatal Research Network over four time periods (74, 80, 84, and 85 percent in 1988, 1990 to 1991, 1995 to 1996, and 1997 to 2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Continued improved survival was observed in a subsequent study from the Vermont Oxford Network of 355,806 North American VLBW infants, with rates increasing from 86 percent in 2000 to 88 percent in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/23\">",
"     23",
"    </a>",
"    ]. Major morbidity for VLBW survivors (defined as bacterial infection, late fungal infection, necrotizing enterocolitis, bronchopulmonary dysplasia, severe intraventricular hemorrhage or retinopathy of prematurity, or periventricular leukomalacia) also decreased from 46 percent in 2000 to 41 percent in 2009. In addition, survival for infants with birth weights between 501 and 750 g improved from 58 percent in 2000 to 63 percent in 2009. However, 89 percent of these infants either died or survived with a major morbidity.",
"   </p>",
"   <p>",
"    Similar improved survival was also noted in a population-based British study of extremely premature infants (defined as gestational age between 22 and 26 weeks) for cohorts born in 1995 and 2006 (40 to 53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/24\">",
"     24",
"    </a>",
"    ]. Survival increased from 1995 to 2006 with each week of gestation (9.5, 12, and 16 percent for 23, 24, and 25 weeks gestation). The median age of death also increased from two days in 1995 to seven days in 2006, which reflected, in part, a shift in the cause of death from early respiratory failure to later complications of prematurity including infection and necrotizing enterocolitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Standard of neonatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival rates for VLBW infants are higher in centers that deliver a high volume of VLBW infants and provide the highest level of neonatal care (ie, level 3 neonatal intensive care unit [NICU]), as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from California that linked birth and death certificate data from 48,237 VLBW infants born between 1991 and 2000 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/25\">",
"       25",
"      </a>",
"      ], the highest survival rates for VLBW were in hospitals that had a level 3 NICU and an annual delivery rate of VLBW infants greater than 100 deliveries. In comparison, the lowest survival rate occurred in hospitals with level 1 care (no NICU) and an annual delivery rate of VLBW infants less than 10 (OR 2.72, 95% CI 2.37-3.12).",
"     </li>",
"     <li>",
"      A meta-analysis of 41 articles including the above study demonstrated a risk-adjusted increased death rate for VLBW and VPT (gestational age &le;32 weeks) infants born at centers without a level 3 NICU compared with those born centers with a level 3 NICU [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/26\">",
"       26",
"      </a>",
"      ]. Calculated",
"      <strong>",
"       risk-adjusted",
"      </strong>",
"      odds ratio based on data from studies determined to be of adequate or high quality demonstrated higher mortality rates for infants born in non-level 3 hospitals for VLBW (adjusted OR, 1.62, 95% CI, 1.44-1.83) and VPT infants (adjusted OR, 1.55; 95% CI, 1.21-1.98).",
"      <strong>",
"       Unadjusted",
"      </strong>",
"      pooled mortality rates comparing infants born at non-level 3 centers to those born at level 3 centers were 38 versus 23 percent in VLBW infants and 15 versus 17 in VPT infants. Subgroup analysis of ELBW infants demonstrated similar results with increased death rates for those born at a non-level 3 center for both unadjusted mortality (59 versus 32 percent) and calculated risk-adjusted odds ratio (adjusted OR 1.8; 95% 1.31-2.46).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support perinatal regionalization with maternal transport of women at-risk to deliver a VLBW infant to a center that delivers a high volume of VLBW infants and provides level 3 neonatal care.",
"   </p>",
"   <p>",
"    In the United States, about three-fourths of VLBW infants are admitted to a NICU based on representative data from 19 states [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/27\">",
"     27",
"    </a>",
"    ]. Data did not distinguish between infants admitted at the facility of birth and those who were transported to a NICU from another facility. Using multivariate analysis, preterm delivery, multiple births, and cesarean delivery were associated with a greater likelihood of NICU admission among VLBW infants.",
"   </p>",
"   <p>",
"    Substandard neonatal care is associated with increased mortality. A case-control study of the Confidential Enquiry into Maternal and Child Health (CEMACH) program in Great Britain, which matched all neonatal deaths (excluding those due to lethal malformations) in infants born at 27 to 28 weeks gestation in the United Kingdom during a two year period (1998 to 2000) with randomly selected survivors, showed increased infant mortality was associated with substandard neonatal care and early neonatal factors including fetal compromise but not maternal characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/28\">",
"     28",
"    </a>",
"    ]. Areas where poor neonatal care were associated with an increased risk of dying included:]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia &ndash; Infants who died were more likely to be hypothermic (temperature &le;36&ordm;C) on admission to the neonatal intensive care unit (NICU) (73 versus 59 percent).",
"     </li>",
"     <li>",
"      Substandard ventilatory and cardiovascular management &ndash; Infants who died compared with survivors received substandard ventilatory (20 versus 7 percent) and cardiovascular care (15 versus 7 percent). Substandard care was defined as a failure to monitor or properly document blood gases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood pressure, and make therapeutic adjustment to maintain blood gases",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood pressure within standard limits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103103346\">",
"    <span class=\"h4\">",
"     AAP policy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2012 American Academy of Pediatrics Committee on Fetus and Newborn policy statement, guidelines recommend regionalized systems of perinatal care to ensure that each newborn is cared for in the most appropriate facility for",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    health, and that VLBW and VPT premature infants be delivered in a facility with a level 3 NICU unless this is precluded by the mother&rsquo;s condition or geographic constraints [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/29\">",
"     29",
"    </a>",
"    ]. The statement clearly defines four levels of newborn care based on the intended patient population and the diseases that are commonly encountered, and covers the requirements for equipment, personnel, ancillary services, and transport capabilities needed to care for these neonates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature infants with major congenital anomalies have higher mortality and morbidity rates. In a study from the NICHD Neonatal Research Network, ELBW infants with congenital anomalies (eg, cardiac, renal, central nervous system anomalies, and chromosomal abnormalities) who survived the first 12 hours of life compared with those without any congenital abnormality had a higher mortality rate in the first 18 to 22 months of corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Premature survivors with major congenital anomalies were twice as likely to have neurodevelopmental impairment, have poor growth, and were at threefold greater risk of rehospitalization when compared with ELBW infants without major anomalies. In another report from the NICHD Neonatal Research Network, ELBW infants with congenital heart disease (0.8 percent of the cohort), compared with those without any major birth defect, had an increased risk of mortality (48 versus 35 percent) and poorer growth [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In particular, major chromosomal anomalies in VLBW infants are associated with poor survival [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/32\">",
"     32",
"    </a>",
"    ]. This was illustrated in a prospective study from the Vermont Oxford Network that noted the prevalence and birth hospital mortality of the following autosomal trisomies in liveborn VLBW infants:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevalence: Trisomy 21 (0.31 percent), trisomy 18 (0.26 percent), trisomy 13 (0.08 percent), and triploidy (0.02 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality: Trisomy 21 (33 percent), trisomy 18 (89 percent), trisomy 13 (92 percent), and triploidy (91 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115075496\">",
"    <span class=\"h2\">",
"     Time of death during birth hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;In VLBW infants, about 50 percent of deaths occur in the first three days after delivery. This was illustrated by a study based on information from the National Inpatient Sample Database from 1997 to 2004 that included 115,350 VLBW infants [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with congenital anomalies were excluded from the analysis. In this cohort, the distribution of birth weights was 10.6, 18.4, 16.9, and 54.1 percent for infants weighing &lt;500 g, 500 to 749 g, 750 to 999 g, and 1000 to 1499 g, respectively. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall survival rate was 77.5 percent. On the first day, 35 percent of the deaths occurred. By the end of the first 3 days and the 28",
"      <sup>",
"       th",
"      </sup>",
"      day, 58 and 90 percent of the deaths occurred.",
"     </li>",
"     <li>",
"      Deaths were more frequent for ELBW infants during the first day of life. Morality increased with decreasing birth weights as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For infants with birth weights &lt;500 g, only 8 percent survived. Most of the deaths (72 percent) occurred in the first day of life and by the end of the third day 86 percent of deaths had occurred.",
"     </li>",
"     <li>",
"      For infants born between 500 and 749 g, the overall mortality rate was 49.2 percent, with 19.6 and 31.4 percent mortality at the end of the first and third day of life.",
"     </li>",
"     <li>",
"      For infants born between 750 and 1000 g, the overall mortality was 14.9 percent, with 3.1 and 6.4 percent mortality at the end of the first and third day of life.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a study from the NICHD of 9575 VLBW infants, the overall mortality rate was 28 percent, and the highest mortality rate occurred in the first 12 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87765208\">",
"    <span class=\"h2\">",
"     Post-discharge mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following discharge from the NICU, preterm infants continue to be at risk for early death. In a retrospective study from the NICHD, 2 percent of ELBW infants died following discharge from the NICU by 18 to 22 months corrected age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/35\">",
"     35",
"    </a>",
"    ]. Multivariate logistic regression analysis identified African American ethnicity, unknown maternal insurance, and a neonatal hospital stay &gt;120 days as predictors of post-discharge mortality. In contrast, maternal exposure to intrapartum antibiotics was associated with decreased risk of mortality.",
"   </p>",
"   <p>",
"    Survivors of prematurity beyond the first years of life still remain at risk for early death compared with those born at term. In a population-based study from Norway of over 1,000,000 individuals born between 1967 and 1988 and followed through 2002, those born prematurely (5.2 percent of the overall group) had an increased risk of death throughout childhood compared with individuals born full-term [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14520/abstract/36\">",
"     36",
"    </a>",
"    ]. Mortality rates were greater for those born extremely premature (gestational age 22 to 27 weeks) and were generally higher for boys compared with girls at the same gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=see_link\">",
"       \"Patient information: When a baby is born premature (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prematurity is defined as a birth that occurs before 37 completed weeks (less than 259 days) of gestation. Premature infants are classified by birth weight or gestational age (",
"      <a class=\"graphic graphic_table graphicRef57685 \" href=\"UTD.htm?1/8/1163\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef81379 \" href=\"UTD.htm?10/59/11197\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, about 12 percent of live births are premature and about 2 percent are born at a gestational age less than 32 weeks (",
"      <a class=\"graphic graphic_figure graphicRef72127 \" href=\"UTD.htm?20/43/21182\">",
"       figure 1",
"      </a>",
"      ). There has been a 21 percent rise in the overall proportion of preterm births since 1990, which is reflected in all stages of prematurity. Part of this increase in premature births is due to the increase of infants with multiple gestations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 80 percent of preterm deliveries occur spontaneously as a result of preterm labor (50 percent) or preterm rupture of membranes (30 percent); intervention for maternal or fetal problems account for the remaining 20 percent (",
"      <a class=\"graphic graphic_table graphicRef74561 \" href=\"UTD.htm?7/40/7819\">",
"       table 4",
"      </a>",
"      ). The four primary causes that lead to preterm labor and delivery are activation of the maternal or fetal hypothalamic-pituitary-adrenal axis, infection, decidual hemorrhage, and pathological uterine distention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Risk factors associated with preterm birth include obstetric and sociodemographic factors (",
"      <a class=\"graphic graphic_table graphicRef68992 \" href=\"UTD.htm?27/48/28428\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"       \"Risk factors for preterm labor and delivery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Low birth weight and prematurity are major contributors to infant mortality. In the United States, prematurity was associated with approximately 37 percent of infant deaths. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased mortality rates in premature infants are associated with the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Increasing immaturity (ie, decreasing birthweight and gestational age) (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Gestational age and birth weight'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hospitals with lower levels of resource and experience in delivering neonatal intensive care (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Standard of neonatal care'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Congenital anomalies (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Congenital anomalies'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvements in newborn intensive care, including the use of surfactant treatment and antenatal steroid therapy to prevent and treat neonatal respiratory distress syndrome, have resulted in decreased mortality rates of preterm infants, except in those who are at the limit of viability. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Trends over time'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=see_link\">",
"       \"Limit of viability\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/1\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2005 period linked birth/infant death data set. Natl Vital Stat Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     WHO, March of Dimes, Partnership for Maternal, Newborn &amp; Child Health, Save the Children. Born too soon: the global action report on preterm birth www.who.int/maternal_child_adolescent/documents/born_too_soon/en/ (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/3\">",
"      Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 2012; 379:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/4\">",
"      Hamilton BE, Hoyert DL, Martin JA, et al. Annual summary of vital statistics: 2010-2011. Pediatrics 2013; 131:548.",
"     </a>",
"    </li>",
"    <li>",
"     Hamilton BE, Martin JA, Ventura SJ. Births: Preliminary data for 2011. Natl Vital Stat Rep 2012. file://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61_05.pdf (Accessed on March 12, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/6\">",
"      Markestad T, Kaaresen PI, R&oslash;nnestad A, et al. Early death, morbidity, and need of treatment among extremely premature infants. Pediatrics 2005; 115:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/7\">",
"      Teitler JO, Reichman NE, Nepomnyaschy L, Martinson M. A cross-national comparison of racial and ethnic disparities in low birth weight in the United States and England. Pediatrics 2007; 120:e1182.",
"     </a>",
"    </li>",
"    <li>",
"     Behrman RE, Butler AS. Preterm Birth, Causes, Consequences, and Prevention, The National Academies Press, Washington, DC 2007.",
"    </li>",
"    <li>",
"     Mathews TJ, MacDorman MF. Infant mortality statistics from the 2007 period linked birth/infant death data set. Naational Vital Statistics Reports 2011;59:1. file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_06.pdf (Accessed on September 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/10\">",
"      Zeitlin J, El Ayoubi M, Jarreau PH, et al. Impact of fetal growth restriction on mortality and morbidity in a very preterm birth cohort. J Pediatr 2010; 157:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/11\">",
"      Tyson JE, Parikh NA, Langer J, et al. Intensive care for extreme prematurity--moving beyond gestational age. N Engl J Med 2008; 358:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/12\">",
"      Field DJ, Dorling JS, Manktelow BN, Draper ES. Survival of extremely premature babies in a geographically defined population: prospective cohort study of 1994-9 compared with 2000-5. BMJ 2008; 336:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/13\">",
"      Itabashi K, Horiuchi T, Kusuda S, et al. Mortality rates for extremely low birth weight infants born in Japan in 2005. Pediatrics 2009; 123:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/14\">",
"      Bassler D, Stoll BJ, Schmidt B, et al. Using a count of neonatal morbidities to predict poor outcome in extremely low birth weight infants: added role of neonatal infection. Pediatrics 2009; 123:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/15\">",
"      Wyckoff MH, Salhab WA, Heyne RJ, et al. Outcome of extremely low birth weight infants who received delivery room cardiopulmonary resuscitation. J Pediatr 2012; 160:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/16\">",
"      Kent AL, Wright IM, Abdel-Latif ME, New South Wales and Australian Capital Territory Neonatal Intensive Care Units Audit Group. Mortality and adverse neurologic outcomes are greater in preterm male infants. Pediatrics 2012; 129:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/17\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2004 period linked birth/infant death data set. Natl Vital Stat Rep 2007; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     Premature birth in the United States black population. Available at: www.marchofdimes.com/files/AA_PTB_Report_FINAL910.pdf/ (Accessed on June 06, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/19\">",
"      Lemons JA, Bauer CR, Oh W, et al. Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics 2001; 107:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/20\">",
"      Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 2007; 196:147.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/21\">",
"      Bode MM, D'Eugenio DB, Forsyth N, et al. Outcome of extreme prematurity: a prospective comparison of 2 regional cohorts born 20 years apart. Pediatrics 2009; 124:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/22\">",
"      Zeitlin J, Ancel PY, Delmas D, et al. Changes in care and outcome of very preterm babies in the Parisian region between 1998 and 2003. Arch Dis Child Fetal Neonatal Ed 2010; 95:F188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/23\">",
"      Horbar JD, Carpenter JH, Badger GJ, et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics 2012; 129:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/24\">",
"      Costeloe KL, Hennessy EM, Haider S, et al. Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies). BMJ 2012; 345:e7976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/25\">",
"      Phibbs CS, Baker LC, Caughey AB, et al. Level and volume of neonatal intensive care and mortality in very-low-birth-weight infants. N Engl J Med 2007; 356:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/26\">",
"      Mathews TJ, Menacker F, MacDorman MF. Infant mortality statistics from the 2000 period linked birth/infant death data set. Natl Vital Stat Rep 2002; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Neonatal intensive-care unit admission of infants with very low birth weight --- 19 States, 2006. MMWR Morb Mortal Wkly Rep 2010; 59:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/28\">",
"      Acolet D, Elbourne D, McIntosh N, et al. Project 27/28: inquiry into quality of neonatal care and its effect on the survival of infants who were born at 27 and 28 weeks in England, Wales, and Northern Ireland. Pediatrics 2005; 116:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/29\">",
"      American Academy of Pediatrics Committee on Fetus And Newborn. Levels of neonatal care. Pediatrics 2012; 130:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/30\">",
"      Walden RV, Taylor SC, Hansen NI, et al. Major congenital anomalies place extremely low birth weight infants at higher risk for poor growth and developmental outcomes. Pediatrics 2007; 120:e1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/31\">",
"      Pappas A, Shankaran S, Hansen NI, et al. Outcome of extremely preterm infants (&lt;1,000 g) with congenital heart defects from the National Institute of Child Health and Human Development Neonatal Research Network. Pediatr Cardiol 2012; 33:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/32\">",
"      Boghossian NS, Horbar JD, Carpenter JH, et al. Major chromosomal anomalies among very low birth weight infants in the Vermont Oxford Network. J Pediatr 2012; 160:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/33\">",
"      Mohamed MA, Nada A, Aly H. Day-by-day postnatal survival in very low birth weight infants. Pediatrics 2010; 126:e360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/34\">",
"      Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/35\">",
"      De Jesus LC, Pappas A, Shankaran S, et al. Risk factors for post-neonatal intensive care unit discharge mortality among extremely low birth weight infants. J Pediatr 2012; 161:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14520/abstract/36\">",
"      Swamy GK, Ostbye T, Skjaerven R. Association of preterm birth with long-term survival, reproduction, and next-generation preterm birth. JAMA 2008; 299:1429.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4966 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14520=[""].join("\n");
var outline_f14_11_14520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Multiple gestation and ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS FOR PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gestational age and birth weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Extremely preterm infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6163667\">",
"      Gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ethnicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Level of neonatal care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Trends over time",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Standard of neonatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103103346\">",
"      AAP policy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H115075496\">",
"      Time of death during birth hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87765208\">",
"      Post-discharge mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4966\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4966|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/43/21182\" title=\"figure 1\">",
"      Preterm birth rate in the United States",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/13/16607\" title=\"figure 2\">",
"      Infant mortality based on race and ethnicity of mother",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4966|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/8/1163\" title=\"table 1\">",
"      Definition of prematurity based on birth weights",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11197\" title=\"table 2\">",
"      Birth weight by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/10/2220\" title=\"table 3\">",
"      Preterm birth rates US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7819\" title=\"table 4\">",
"      Proportion of preterm birth by etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28428\" title=\"table 5\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/11/22713?source=related_link\">",
"      Late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/1/27672?source=related_link\">",
"      Limit of viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34922?source=related_link\">",
"      Long-term neurodevelopmental outcome of premature infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/38/2659?source=related_link\">",
"      Patient information: When a baby is born premature (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/34/43561?source=related_link\">",
"      Prevention and treatment of respiratory distress syndrome in preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31992?source=related_link\">",
"      Short-term complications of the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/27/43449?source=related_link\">",
"      Strategies to control the rate of high order multiple gestation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14521="Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities";
var content_f14_11_14521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant and neoadjuvant chemotherapy for soft tissue sarcoma of the extremities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14521/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/11/14521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Soft tissue sarcomas (STS) are uncommon malignant tumors that arise from extraskeletal connective tissues, including the peripheral nervous system. They can arise at any body site, but are most common in the extremities, particularly the lower limbs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227086#H12227086\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In treating STS of the extremities, the major therapeutic goals are long-term survival, avoidance of a local recurrence, maximizing function, and minimizing morbidity. Surgical resection is the cornerstone of potentially curative treatment. For nearly all patients with extremity sarcomas &gt;5 cm, the addition of radiation therapy (RT) improves local control, and it has also had a significant impact on limb salvage. There are advantages to preoperative (neoadjuvant) as compared to postoperative (adjuvant) administration of RT, and for neoadjuvant therapy utilizing combinations of RT and chemotherapy, particularly for recurrent and large, high-grade primary tumors. These topics are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic chemotherapy is a routine component of treatment for several sarcomas that occur predominantly in children (ie, rhabdomyosarcoma, Ewing sarcoma, and osteogenic sarcoma). However, the value of adjunctive chemotherapy in patients undergoing resection of the adult-type localized extremity STS (eg, leiomyosarcoma, liposarcoma, synovial sarcoma) remains controversial.",
"   </p>",
"   <p>",
"    This topic review will discuss the use of adjuvant and neoadjuvant chemotherapy in the treatment of adult-type extremity STS. The role of chemotherapy in the treatment of retroperitoneal STS, rhabdomyosarcoma and the Ewing sarcoma family of tumors, and neoadjuvant combined modality approaches for patients with large, high-grade or recurrent extremity STS are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link\">",
"     \"Treatment of the Ewing sarcoma family of tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUVANT CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pediatric-type sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of systemic chemotherapy to local therapy significantly improves outcomes for the common pediatric types of sarcoma (rhabdomyosarcoma, osteogenic sarcoma, and the Ewing sarcoma family of tumors of both soft tissue and bone). Most modern treatment plans utilize initial (induction or neoadjuvant) chemotherapy followed by local treatment and additional (adjuvant) chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Rhabdomyosarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients with rhabdomyosarcoma are children. The routine use of multiagent chemotherapy (typically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/21/14679?source=see_link\">",
"     dactinomycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , VActinoC, or regimens used for Ewing sarcoma), in addition to surgery and RT, has contributed significantly toward increasing cure rates among those with localized disease. The rare cases of rhabdomyosarcoma that arise in adults are managed similarly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ewing sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among children, Ewing sarcoma is much more common in bone than in soft tissue, while in adults, it more often presents in soft tissue. Regardless of whether it arises in bone or soft tissue, the tumor is treated in the same multidisciplinary manner in adults as in children. A combination of neoadjuvant and adjuvant chemotherapy using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (VAC), with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , is usually recommended in addition to local therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of the Ewing sarcoma family of tumors\", section on 'Treatment for localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Extraosseous osteogenic sarcomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteosarcomas rarely arise in the soft tissue rather than bone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83187 \" href=\"UTD.htm?8/61/9172\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef83419 \" href=\"UTD.htm?0/6/111\">",
"     image 2",
"    </a>",
"    ). In contrast to Ewing sarcoma, when osteogenic sarcomas arise in soft tissue rather than bone, management has generally followed the principles established for soft-tissue tumors rather than primary bone tumors.",
"   </p>",
"   <p>",
"    While adjuvant chemotherapy is a standard component of treatment for primary bone osteosarcomas in all age groups, it has been thought to be much less effective for tumors of extraosseous origin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/1\">",
"     1",
"    </a>",
"    ]. However, at least one study suggests that outcomes may be better when children with extraosseous osteosarcoma are treated with the same combination chemotherapy protocols as used for bone-primary osteogenic sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=see_link\">",
"     \"Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=see_link\">",
"     \"Chemotherapy and radiation therapy in the management of osteosarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sarcomas more commonly seen in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remainder of this discussion will focus on the use of adjuvant chemotherapy for the more common adult-type STS, such as liposarcomas, leiomyosarcomas, and synovial sarcomas.",
"   </p>",
"   <p>",
"    Over 20 randomized trials and two meta-analyses have addressed the potential benefit of adjuvant chemotherapy for resected extremity STS in adults. Unfortunately, these have yielded conflicting data, and as a result, the benefit of adjuvant chemotherapy remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Early randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of early trials used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    alone or with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    but did not employ",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , a compound only developed in the mid-1980s. Among the first 14 published randomized trials of adjuvant doxorubicin-based therapy versus surgery alone, two reported a significant survival advantage for combination chemotherapy, three found higher survival in the observation arm, and the remainder showed no difference in outcome in the treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     SMAC meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual patient data from these trials, which involved 1568 adults with localized resectable STS (only some of which were localized to an extremity), were analyzed by the Sarcoma Meta-Analysis Collaboration (SMAC) and published in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. All evaluated studies that randomly assigned patients postoperatively to receive or not receive adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing chemotherapy; fewer than 5 percent of patients received a chemotherapy regimen that included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    . The following benefits were noted in the chemotherapy group:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly longer local recurrence-free interval &mdash; hazard ratio [HR] for local recurrence 0.73 (95% CI 0.56-0.94).",
"     </li>",
"     <li>",
"      Significantly longer distant recurrence-free interval &mdash; HR 0.70 (95% CI 0.57-0.85).",
"     </li>",
"     <li>",
"      Significantly higher overall recurrence-free survival &mdash; HR for any recurrence 0.75 (95% CI 0.64-0.87). This corresponded to an absolute 6 to 10 percent improvement in recurrence free survival at 10 years.",
"     </li>",
"     <li>",
"      There was a trend towards better overall survival that favored chemotherapy, but it was not statistically significant (HR for death 0.89, 95% CI 0.76-1.03).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There was no consistent evidence of a difference in any endpoint according to age, sex, stage, site, grade, histology (although there was no central pathology review), extent of resection, tumor size, or exposure to RT. However, the strongest evidence of a beneficial effect on survival was shown in the subset of patients with extremity and truncal sarcomas. Among these patients who received adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -containing chemotherapy, there was a modest but statistically significant benefit for chemotherapy (HR for death 0.80, p = 0.029), which translated into a 7 percent absolute benefit in overall survival at 10 years.",
"   </p>",
"   <p>",
"    The updated meta-analysis from this group, which includes many later trials, is presented below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma\", section on 'Adjuvant chemotherapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Updated meta-analyses'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Later randomized trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the suggestion of a survival benefit for extremity and truncal STS in the SMAC meta-analysis, later randomized trials largely focused on these sites. There are few randomized trials addressing the benefit of adjuvant chemotherapy for visceral or head and neck soft tissue sarcomas.",
"   </p>",
"   <p>",
"    Four additional randomized trials explored the benefit of anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -based combination adjuvant chemotherapy in extremity STS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/6-10\">",
"     6-10",
"    </a>",
"    ], two of which suggest a possible survival benefit for adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an Italian trial in which 46 percent of the enrolled patients had either synovial sarcoma or liposarcoma (two relatively chemosensitive histologies), 104 patients with high grade large (&ge;5 cm) or recurrent spindle cell sarcomas involving the extremities or girdles were randomly assigned to no postoperative therapy or to five cycles of chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Chemotherapy consisted of a dose intensive",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"        epirubicin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"        ifosfamide",
"       </a>",
"      </span>",
"      combination (epirubicin 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 2 plus ifosfamide 1.8",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 to 5) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      support. Accrual was prematurely discontinued at two years, when a significant difference in the cumulative incidence of distant metastasis was found (45 versus 28 percent), favoring the chemotherapy group.",
"      <br/>",
"      <br/>",
"      Four-year overall survival was significantly greater in favor of chemotherapy (69 versus 50 percent), but the difference that favored the chemotherapy group lost statistical significance with median follow-up of over seven years, a finding that was attributed to the limited number of enrolled patients. Curiously, overall relapse rates (local and distant) were similar in the two groups (44 and 45 percent).",
"      <br/>",
"      <br/>",
"      It is difficult to interpret these results, since the main expected benefit of adjuvant systemic chemotherapy is to reduce the rate of distant relapse. However, this may have reflected a preponderance of patients with local recurrence later amenable to local surgical salvage approaches.",
"     </li>",
"     <li>",
"      A follow-up Italian trial randomly assigned 88 patients with high-risk extremity sarcoma to surgery with or without RT (n = 43) or to surgery plus chemotherapy (n = 45, 26 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      alone, and 19 to epirubicin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ) with or without RT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/8\">",
"       8",
"      </a>",
"      ]. The five-year survival rate of patients treated with chemotherapy was significantly higher than that of patients who did not receive chemotherapy (72 versus 47 percent). However, the large number of treatment variables and the small number of studied patients makes interpretation of this result difficult.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these results, a survival benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -containing chemotherapy could not be shown in two other trials [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EORTC randomly assigned 351 patients with completely resected STS (67 percent extremity tumors, 60 percent high-grade, 40 percent &ge;10 cm) to observation versus five cycles of adjuvant chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per cycle) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/10\">",
"       10",
"      </a>",
"      ]. The estimated five-year relapse-free survival was similar in both arms as was overall survival (67 versus 68 percent, HR 0.94, 95% CI 0.68-1.31). Interpretation of these results is limited by the inclusion of patients with nonextremity, small, and",
"      <span class=\"nowrap\">",
"       low/intermediate-grade",
"      </span>",
"      primaries, as well as the relatively low ifosfamide dose.",
"     </li>",
"     <li>",
"      An Austrian trial of 59 patients assigned to perioperative chemotherapy or surgery alone was also negative, but the small number of patients makes it likely that the study was underpowered to detect a small difference between the arms, if one were present [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Updated meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;An updated 2008 meta-analysis was conducted on published data from 18 randomized trials of 1953 patients with localized and potentially resectable soft tissue sarcoma that were reported between 1973 and 2002, including the Austrian and both Italian trials discussed above, but not the most recent large EORTC trial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"     11",
"    </a>",
"    ]. Five of the trials used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , while the others used doxorubicin alone or in combination with other agents.",
"   </p>",
"   <p>",
"    The odds ratio (OR) for local recurrence was 0.73 (95% CI 0.56 to 0.94) in favor of chemotherapy; the corresponding value for distant and overall recurrence was 0.67 (95% CI 0.56 to 0.82), again favoring chemotherapy. These values are nearly identical to those found in the earlier meta-analysis (see",
"    <a class=\"local\" href=\"#H9\">",
"     'SMAC meta-analysis'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    However, in contrast to the earlier analysis, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    was associated with a statistically significant overall survival benefit (OR for death 0.56, 95% CI 0.36 to 0.85). The absolute risk reduction for doxorubicin in combination with ifosfamide was 11 percent (30 versus 41 percent risk of death). Benefit could not be shown for doxorubicin alone (OR 0.84, 95% CI 0.68 to 1.03), implying the fundamental importance of ifosfamide in the adjuvant treatment of sarcomas overall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pooled analysis of the EORTC trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to this result, a pooled analysis of individual patient data from the two largest adjuvant trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    -based chemotherapy (both performed by the EORTC [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/10,12\">",
"     10,12",
"    </a>",
"    ] and totaling 819 patients) presented at the 2008 ASCO meeting was negative [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/13\">",
"     13",
"    </a>",
"    ]. Compared to surgery alone, the use of postoperative adjuvant chemotherapy was not associated with a significant survival benefit, except in the subset of patients undergoing incomplete (R1) resection. In multivariate analysis, tumor size, histologic subtype, and grade were not associated with any progression-free or overall survival benefit from adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Impact of histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant clinical trials in adult sarcomas have, out of necessity, included patients with multiple histologies, in contrast to pediatric studies, which focus on one specific sarcoma subtype. It is well recognized that",
"    <span class=\"nowrap\">",
"     myxoid/round",
"    </span>",
"    cell liposarcomas and synovial sarcomas are relatively chemosensitive subtypes of STS, at least in the setting of metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H5#H5\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Histologic subtype and response to chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although it has been proposed that the benefit of adjuvant chemotherapy may be preferentially seen when patients are selected based upon tumor histology, grade [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/14\">",
"     14",
"    </a>",
"    ] or tumor size, this hypothesis has never been validated in a prospective clinical trial in adult sarcoma patients, nor in any of the pooled analyses of randomized trial data [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11,13\">",
"     11,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, the results from retrospective reports evaluating adjuvant chemotherapy in patients with the more chemotherapy-sensitive histologic subtypes are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. While three contemporary retrospective series suggest a potential survival benefit for adjuvant chemotherapy in patients with the liposarcoma and synovial sarcoma subtypes of extremity STS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/15,16,18\">",
"     15,16,18",
"    </a>",
"    ], two others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/17,19\">",
"     17,19",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benefit for adjuvant chemotherapy was suggested in a single-center Italian report of 251 patients (aged 5 to 87 years) with a localized synovial sarcoma [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/16\">",
"       16",
"      </a>",
"      ]. Adjuvant chemotherapy was administered to 61 of 215 patients who had a macroscopically complete resection (28 percent), while the remainder received no adjuvant systemic therapy. Five-year metastasis-free survival was greater for those treated with chemotherapy (60 versus 48 percent), and benefit appeared to be greatest for patients aged 17 or older who had tumors measuring &gt;5 cm (five-year metastasis-free survival 47 versus 27 percent, respectively).",
"     </li>",
"     <li>",
"      On the other hand, a lack of long-term benefit from adjuvant chemotherapy was suggested in a report of the combined experience of two major cancer cancers (MSKCC and M. D. Anderson) that included 674 consecutive adults undergoing resection of a high-grade, &ge;5 cm extremity STS between 1984 and 1999 [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/17\">",
"       17",
"      </a>",
"      ]. Adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      -based chemotherapy was administered to 336 (50 percent), while the remainder received local therapy only.",
"      <br/>",
"      <br/>",
"      Although not a randomized trial, there were no statistically significant differences between the chemotherapy and local therapy alone groups with respect to tumor size, anatomic site, histopathologic subtype, or resection margin status. With a median follow-up of 6.1 years, the effect of chemotherapy appeared to vary over time. During the first year, the HR for disease-specific survival for chemotherapy versus no chemotherapy was 0.37 (95% CI 0.20-0.69); thereafter, the HR was 1.36 (95% CI 1.02-1.81) and did not vary according to histology or tumor size.",
"      <br/>",
"      <br/>",
"      Interpretation of retrospective data such as these is hampered because several biases are operative that favor the control arm:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chemotherapy was likely recommended for those patients whose tumors were thought to have the highest risk of recurrence, while those thought to have more favorable outcomes were not offered chemotherapy.",
"     </li>",
"     <li>",
"      Although none of the differences were statistically significant, there were differences in tumor histology and size between the two groups. In the combined report from MSKCC and M. D. Anderson, 50 percent of the patients who did not receive chemotherapy had 5 to 10 cm primary tumors, while only 42 percent of those receiving chemotherapy had this relatively favorable tumor size. It is well recognized that the risk of metastasis increases for every centimeter increase in the size of a primary sarcoma. In addition, 21 percent of the control patients had liposarcoma histology compared to 14 percent in the treatment group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data can be interpreted positively or negatively; the negative view is that overall survival was not improved with the use of chemotherapy. The positive view is that patients with inferior prognosis had their survival improved to that of lower risk patients with the use of systemic chemotherapy in the adjuvant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of chemotherapy for patients with a resected extremity STS remains uncertain and controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The updated meta-analysis from the Sarcoma Meta-Analysis Collaboration [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"     11",
"    </a>",
"    ] suggests that use of an optimal, adequately dosed",
"    <span class=\"nowrap\">",
"     anthracycline/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"      ifosfamide",
"     </a>",
"     -containing",
"    </span>",
"    regimen significantly prolongs survival in patients with resected extremity STS [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"     11",
"    </a>",
"    ]. However, the analysis did not include data from the single largest negative trial, which so far has been reported only in abstract form [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/12\">",
"     12",
"    </a>",
"    ]. A preliminary report of a pooled analysis of this trial and another European large trial, both of which tested the value of an anthracycline and ifosfamide-containing regimen, indicated no benefit from adjuvant anthracycline-ifosfamide chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, despite the most recent positive meta-analysis, it is difficult to recommend adjuvant chemotherapy as a standard practice for all patients with extremity STS. If there is a survival benefit for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    -based adjuvant chemotherapy, it appears to be small, no more than 5 percent absolute increase in survival at 5 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In keeping with the consensus-based guidelines of the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    and the European Society of Medical Oncology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/22\">",
"     22",
"    </a>",
"    ], which encompass adjuvant chemotherapy as an option for high-risk patients, our present approach is to individualize therapy, taking into consideration the patient's performance status, comorbid factors (including age), site of disease, and histologic subtype (eg, younger patients with synovial sarcoma or the round cell version of myxoid liposarcoma). The potential for benefit from adjuvant chemotherapy must be discussed in the context of expected treatment-related toxicities, including potential sterility in younger people, cardiomyopathy, renal damage, second cancers, and overall impairment of quality of life.",
"   </p>",
"   <p>",
"    Even for those patients in whom the decision has been made to administer adjuvant chemotherapy, the optimal regimen is undefined. We prefer five to six cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (usually 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle in split bolus doses or continuous infusion over three days),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (9 to 10",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    in split doses over three hours per day for three to four days), with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    [AIM (",
"    <a class=\"graphic graphic_table graphicRef67985 \" href=\"UTD.htm?40/20/41294\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef81370 \" href=\"UTD.htm?2/42/2735\">",
"     table 2",
"    </a>",
"    )] rather than MAID (mesna, doxorubicin, ifosfamide, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/23\">",
"     23",
"    </a>",
"    ]) since this permits the administration of maximal doses of the two most active drugs for sarcoma (doxorubicin and ifosfamide), rather than adding myelotoxicity with dacarbazine. Three cycles of chemotherapy may suffice, although the data supporting this statement are limited to a single trial of three versus five cycles of chemotherapy in 328 patients with high-risk (deeply seated, high grade, or large [&ge;5 cm] primary, or locally recurrent) extremity sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/24\">",
"     24",
"    </a>",
"    ]. Given the limitations of the available data, we still consider that five or six cycles of chemotherapy represents the preferred approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"     \"Treatment protocols for soft tissue and bone sarcoma\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Given that the benefit of chemotherapy appears to be dependent upon the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , at least from the most recent meta-analysis, and the known age-dependent toxicities of ifosfamide, it makes a decision to use adjuvant chemotherapy in older patients even more difficult. In view of the uncertainty of long-term benefit for patients with most sarcoma subtypes, extreme caution is indicated in treating elderly patients with adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEOADJUVANT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theoretical advantages to neoadjuvant approaches to therapy include tumor cytoreduction, immediate treatment of micrometastases, and an early indication as to the effectiveness of",
"    <span class=\"nowrap\">",
"     chemotherapy/radiotherapy.",
"    </span>",
"    Cytoreduction may allow less radical surgical resection to be performed, and this approach is often considered in patients with large extremity sarcomas, particularly if the patient is a borderline candidate for limb salvage surgery.",
"   </p>",
"   <p>",
"    Most often, when induction therapy is considered for a patient with a large or recurrent extremity sarcoma, particularly if limb salvage is an issue, radiotherapy is chosen with or without chemotherapy. Adjuvant radiotherapy with and without chemotherapy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H12#H12\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Initial chemoradiotherapy for large high-grade STS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Preoperative chemoradiotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of induction chemotherapy alone in this setting is uncertain. Adequately powered, randomized phase III trials are not available, and the results of uncontrolled studies are conflicting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A randomized phase II EORTC study in which 150 patients were randomly assigned to three cycles of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per cycle) versus surgery alone failed to show better survival in the chemotherapy arm, and the trial was stopped before expansion into a phase III study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/27\">",
"     27",
"    </a>",
"    ]. The low chemotherapy intensity used in this study may have contributed to the negative result.",
"   </p>",
"   <p>",
"    At least some data supports the use of neoadjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/52/41798?source=see_link\">",
"     trabectedin",
"    </a>",
"    , where available, in patients with locally advanced myxoid liposarcoma. In an uncontrolled study of 23 patients, seven had an objective partial response, and at surgery, three had a pathologic complete response after three to six cycles of trabectedin (1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours, once every 21 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/28\">",
"     28",
"    </a>",
"    ]. Trabectedin is available in Europe and in some other countries, but not in the US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=see_link&amp;anchor=H23#H23\">",
"     \"Systemic treatment of metastatic soft tissue sarcoma\", section on 'Trabectedin'",
"    </a>",
"    .) Given the lack of data regarding the impact of adjuvant or neoadjuvant trabectedin on long-term outcomes, its use in these settings is still considered experimental.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chemotherapy with regional hyperthermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A European randomized trial reported benefit from the addition of regional hyperthermia to neoadjuvant chemotherapy compared to neoadjuvant chemotherapy alone among patients with large high grade tumors, or initially unresectable disease. This approach, which is not widely used outside of Europe, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Chemotherapy with regional hyperthermia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of neoadjuvant chemotherapy in the management of STS remains undefined. Nevertheless,",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines suggest that preoperative chemotherapy (followed by postoperative RT) is an acceptable alternative to preoperative RT or preoperative chemoradiotherapy for patients with large (&gt;10 cm) potentially resectable STS or if there is concern for adverse functional outcomes from initial surgery. For most of these patients, we prefer radiation therapy with or without chemotherapy rather than chemotherapy alone.",
"   </p>",
"   <p>",
"    These patients should be managed in a center with multidisciplinary expertise in the management of STS, and ideally, treatment should be administered in the context of a clinical trial. If such a trial is not available or if patients are ineligible, we suggest sequential rather than concurrent chemotherapy and RT. We administer chemotherapy first (typically AIM rather than MAID) followed by RT and then surgery. Others utilize concomitant chemoradiotherapy using low radiosensitizing doses of chemotherapy during RT. The specific approach used remains a function of an institution's experience and expertise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H12#H12\">",
"     \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Initial chemoradiotherapy for large high-grade STS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=see_link\">",
"       \"Patient information: Soft tissue sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical resection is the cornerstone of treatment for virtually all patients with an extremity soft tissue sarcoma. The combination of surgery and radiation therapy (RT) achieves better outcomes than either treatment alone for nearly all intermediate- and high-grade soft tissue sarcomas more than 5 cm in greatest dimension. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic chemotherapy is a routine component of treatment for several soft tissue sarcomas that occur predominantly in children (ie, rhabdomyosarcoma, Ewing sarcoma). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pediatric-type sarcomas'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      However, despite many randomized trials, the role of adjuvant chemotherapy for the more common adult subtypes of soft tissue sarcoma (such as liposarcoma, synovial sarcoma, and leiomyosarcoma) remains uncertain:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The most recent analysis from the Sarcoma Meta-Analysis Collaboration (SMAC) suggests a significant 11 percent improvement in survival for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      -based adjuvant chemotherapy compared to resection alone [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, a pooled analysis of individual patient data from the two largest adjuvant trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      -based chemotherapy (both performed by the EORTC [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/10,12\">",
"       10,12",
"      </a>",
"      ], only one of which was included in the SMAC meta-analysis) presented at the 2008 ASCO meeting was completely negative [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pooled analysis of the EORTC trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no evidence that adjuvant chemotherapy is relatively more beneficial for the chemotherapy-sensitive subtypes of STS. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Impact of histology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, in our view, this approach cannot be adopted as a standard treatment for all extremity soft tissue sarcomas, regardless of histology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In keeping with the guidelines of the",
"      <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"       National Comprehensive Cancer Network (NCCN)",
"      </a>",
"      and the European Society for Medical Oncology [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14521/abstract/22\">",
"       22",
"      </a>",
"      ], we suggest that the appropriateness of adjuvant chemotherapy be addressed on a case by case basis, taking into consideration the patient's performance status, comorbid factors (including age), disease location, tumor size, and histologic subtype. The potential for benefit must be discussed in the context of expected treatment-related toxicities including sterility in younger individuals, cardiomyopathy, renal damage, second cancers, and overall impairment of quality of life.",
"      <br/>",
"      <br/>",
"      For patients who decide to undergo adjuvant chemotherapy despite the uncertainty of benefit and the potential for treatment-related toxicity, we recommend using a regimen that contains both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). We prefer doxorubicin plus ifosfamide and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      [AIM (",
"      <a class=\"graphic graphic_table graphicRef81370 \" href=\"UTD.htm?2/42/2735\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67985 \" href=\"UTD.htm?40/20/41294\">",
"       table 1",
"      </a>",
"      )] rather than the MAID regimen. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Summary'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=see_link\">",
"       \"Treatment protocols for soft tissue and bone sarcoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neoadjuvant therapy is most often considered in the setting of a large or recurrent high-grade tumor, particularly if limb salvage is an issue. In these situations, RT is most commonly selected with or without chemotherapy. The optimal neoadjuvant regimen, and how best to integrate radiation therapy, chemotherapy, and surgery are unknown. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=see_link&amp;anchor=H12#H12\">",
"       \"Local treatment for primary soft tissue sarcoma of the extremities and chest wall\", section on 'Initial chemoradiotherapy for large high-grade STS'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Preoperative chemoradiotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of induction chemotherapy alone in this setting is uncertain. However,",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines indicate that preoperative RT alone, preoperative chemotherapy (with postoperative RT), or preoperative chemoradiotherapy are all acceptable options. Where available, another option is neoadjuvant chemotherapy combined with regional hyperthermia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities\", section on 'Chemotherapy with regional hyperthermia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data to support one approach over the other, and the specific neoadjuvant approach chosen typically depends upon institutional expertise and experience. If possible, we prefer that these patients be treated in the context of a clinical trial.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/1\">",
"      Ahmad SA, Patel SR, Ballo MT, et al. Extraosseous osteosarcoma: response to treatment and long-term outcome. J Clin Oncol 2002; 20:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/2\">",
"      Goldstein-Jackson SY, Gosheger G, Delling G, et al. Extraskeletal osteosarcoma has a favourable prognosis when treated like conventional osteosarcoma. J Cancer Res Clin Oncol 2005; 131:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/3\">",
"      Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol 1997; 24:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/4\">",
"      Sarcoma Meta-analysis Collaboration (SMAC). Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev 2000; :CD001419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/5\">",
"      Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997; 350:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/6\">",
"      Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/7\">",
"      Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003; 65 Suppl 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/8\">",
"      Petrioli R, Coratti A, Correale P, et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002; 25:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/9\">",
"      Brodowicz T, Schwameis E, Widder J, et al. Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 2000; 4:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/10\">",
"      Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012; 13:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/11\">",
"      Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/12\">",
"      Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994; 12:1137.",
"     </a>",
"    </li>",
"    <li>",
"     Le Cesne A, Van Glabbeke M, Woll PJ, et al. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: Pooled analysis of the two STBSG-EORTC phase III clinical trials (abstract). J Clin Oncol 2008; 26:559s. (Abstract available online at www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&amp;vmview=abst_detail_view&amp;confID=55&amp;abstractID=31986, accessed August 26, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/14\">",
"      Italiano A, Delva F, Mathoulin-Pelissier S, et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010; 21:2436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/15\">",
"      Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/16\">",
"      Ferrari A, Gronchi A, Casanova M, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 2004; 101:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/17\">",
"      Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004; 22:4567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/18\">",
"      Eilber FC, Brennan MF, Eilber FR, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007; 246:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/19\">",
"      Palmerini E, Staals EL, Alberghini M, et al. Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer 2009; 115:2988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/20\">",
"      Blay JY, Le Cesne A. Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. Oncologist 2009; 14:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/21\">",
"      Schuetze SM, Patel S. Should patients with high-risk soft tissue sarcoma receive adjuvant chemotherapy? Oncologist 2009; 14:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/22\">",
"      Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 Suppl 5:v198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/23\">",
"      Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/24\">",
"      Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012; 30:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/25\">",
"      Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004; 15:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/26\">",
"      Italiano A, Penel N, Robin YM, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009; 20:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/27\">",
"      Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14521/abstract/28\">",
"      Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012; 23:771.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7720 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14521=[""].join("\n");
var outline_f14_11_14521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pediatric-type sarcomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Rhabdomyosarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ewing sarcoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Extraosseous osteogenic sarcomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sarcomas more commonly seen in adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Early randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - SMAC meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Later randomized trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Updated meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pooled analysis of the EORTC trials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Impact of histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEOADJUVANT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chemotherapy with regional hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/7720\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7720|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/61/9172\" title=\"diagnostic image 1\">",
"      Extraosseous osteosarcoma with metastatic disease to the lungs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/6/111\" title=\"diagnostic image 2\">",
"      Surgical specimen of extraosseous osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/7720|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/20/41294\" title=\"table 1\">",
"      AIM 75_9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/42/2735\" title=\"table 2\">",
"      AIM 75_10",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39050?source=related_link\">",
"      Chemotherapy and radiation therapy in the management of osteosarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/23/33146?source=related_link\">",
"      Clinical features, evaluation, and treatment of retroperitoneal soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38650?source=related_link\">",
"      Local treatment for primary soft tissue sarcoma of the extremities and chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20842?source=related_link\">",
"      Osteosarcoma: Epidemiology, pathogenesis, clinical presentation, diagnosis, and histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/26/16802?source=related_link\">",
"      Patient information: Soft tissue sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/49/34586?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41146?source=related_link\">",
"      Systemic treatment of metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27354?source=related_link\">",
"      Treatment of locally recurrent and unresectable, locally advanced soft tissue sarcoma of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/50/14122?source=related_link\">",
"      Treatment of the Ewing sarcoma family of tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7410?source=related_link\">",
"      Treatment protocols for soft tissue and bone sarcoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14522="Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities";
var content_f14_11_14522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Timothy J Friel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14522/contributors\">",
"     David T Scadden, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/11/14522/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/11/14522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shortly after the first description of the acquired immunodeficiency syndrome (AIDS), cytopenias of all major blood cell lines were increasingly recognized among patients infected with the human immunodeficiency virus (HIV). In one early series of patients with AIDS, anemia was noted in approximately 70 percent, lymphopenia in 70 percent, neutropenia in 50 percent, and thrombocytopenia in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of the various cytopenias correlates directly with the degree of immunosuppression. However, isolated abnormalities, particularly thrombocytopenia, may be encountered as the initial presentation of HIV infection. As a result, HIV infection should be considered in the assessment of patients presenting with any type of cytopenia.",
"   </p>",
"   <p>",
"    The causes and treatment of thrombocytopenia and coagulation abnormalities in patients with HIV infection will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar issues regarding anemia, neutropenia, and lymphopenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia is a common finding in individuals infected with HIV, affecting approximately 40 percent of patients during the course of their illness [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/1\">",
"     1",
"    </a>",
"    ]. HIV-associated thrombocytopenia occurs in patients from all major risk groups, including those exposed via homosexual or heterosexual contact, injection drug use, and blood product transfusion.",
"   </p>",
"   <p>",
"    Epidemiologic data provide several pertinent observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients may present with thrombocytopenia at any time during the course of HIV infection, from asymptomatic infection to advanced AIDS.",
"     </li>",
"     <li>",
"      The incidence of platelet abnormalities appears to increase with progressive immunosuppression. In one study, for example, the incidence of a platelet count below",
"      <span class=\"nowrap\">",
"       150,000/microL",
"      </span>",
"      was 8 and 30 percent in HIV-infected patients with CD4 counts of 200 to",
"      <span class=\"nowrap\">",
"       500/microL",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       &lt;200/microL,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thrombocytopenia may be the initial manifestation of HIV infection in as many as 10 percent of patients. Therefore, consideration of HIV testing is essential in the assessment of any patient with newly diagnosed thrombocytopenia.",
"     </li>",
"     <li>",
"      The degree of thrombocytopenia at presentation varies. In one prospective evaluation, 27, 11 and 5 percent of patients had platelet counts &lt;150,000, &lt;100,000, and",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL,",
"      </span>",
"      respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/4\">",
"       4",
"      </a>",
"      ]. However, spontaneous bleeding is rare in patients with platelet counts above",
"      <span class=\"nowrap\">",
"       10,000/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/5\">",
"       5",
"      </a>",
"      ], although prolongation of the bleeding time is detectable with platelet counts up to",
"      <span class=\"nowrap\">",
"       100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      While the incidence of thrombocytopenia appears to have declined in the era of combination antiretroviral therapy, the frequency of platelet counts",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL",
"      </span>",
"      continues to hover between 10 and 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the current era of combination antiretroviral therapy, thrombocytopenia is more commonly encountered among patients with uncontrolled HIV replication and viral hepatitis co-infection. As an example, in a retrospective case-control study of HIV-infected patients, thrombocytopenic patients (ie, platelet counts",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"      for more than three months) were significantly more likely to have HCV co-infection (OR 6.1; 95% CI 1.6-23), cirrhosis (OR 24, 95% CI1.7-338) and detectable HIV viremia (OR 5.3; 95% CI 1.6-17.1) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/7\">",
"       7",
"      </a>",
"      ]. In another international assessment of the prevalence of thrombocytopenia (defined as platelet counts",
"      <span class=\"nowrap\">",
"       &lt;125,000/microL)",
"      </span>",
"      among patients with previously untreated HIV, the frequency of reduced platelet counts correlated with geographic location and Hepatitis B co-infection. Prevalences of thrombocytopenia exceeding 5 percent were observed among patients from India, Brazil, the United States, and Malawi; in contrast, the baseline prevalence of thrombocytopenia was less than 5 percent among patients enrolled from Haiti, Peru, South Africa, and Thailand [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of thrombocytopenia in HIV-infected patients can be divided into two groups: primary HIV-associated thrombocytopenia and secondary thrombocytopenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Primary HIV-associated thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HIV-associated thrombocytopenia (PHAT) is the most common cause of low platelet counts encountered in HIV-infected patients. Clinically, PHAT is similar to classic idiopathic thrombocytopenic purpura (ITP) except that splenomegaly is more commonly noted in patients with PHAT than in ITP. Platelet counts are often higher in HIV-infected patients, and mild thrombocytopenia occasionally resolves without therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of thrombocytopenia in PHAT is complex. Bone marrow examination, as in classic ITP, reveals normal or increased numbers of megakaryocytes in the face of reduced numbers of circulating platelets. This combination suggests the presence of ineffective platelet production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased peripheral destruction. Kinetic studies using radiolabeled autologous platelets from HIV-infected individuals have shown that both factors contribute: there is more than a 50 percent reduction in platelet survival and a 50 percent reduction in platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a comprehensive study comparing the kinetics of the megakaryocyte-platelet system in HIV-infected thrombocytopenic patients with normal controls, the following differences were found [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced platelet survival (87 versus 232 hours)",
"     </li>",
"     <li>",
"      Reduced recovery of infused platelets (33 versus 65 percent)",
"     </li>",
"     <li>",
"      Increased megakaryocyte number [30 x 10",
"      <sup>",
"       6",
"      </sup>",
"      versus 11 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        6",
"       </sup>",
"       /kg]",
"      </span>",
"     </li>",
"     <li>",
"      Reduced marrow megakaryocyte progenitors [3.3 versus 27",
"      <span class=\"nowrap\">",
"       CFU-Meg/1000",
"      </span>",
"      CD34(+) cells]",
"     </li>",
"     <li>",
"      Increased endogenous thrombopoietin (TPO) concentration (596 versus 95",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      and increased TPO receptor number (461 versus 207",
"      <span class=\"nowrap\">",
"       receptors/platelet).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies indicate a triad of shortening of platelet life span by two-thirds, a doubling of splenic platelet sequestration, and ineffective delivery of viable platelets, despite a threefold expansion in marrow megakaryocyte mass driven by TPO.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Reduced platelet survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral destruction of platelets in patients with PHAT is probably due to the presence of antiplatelet antibodies in the serum and on the surface of platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/1,14-20\">",
"     1,14-20",
"    </a>",
"    ]. Platelet-associated IgG crossreacts with the platelet glycoprotein complex",
"    <span class=\"nowrap\">",
"     (GP)IIb/IIIa",
"    </span>",
"    and the HIV envelope glycoproteins",
"    <span class=\"nowrap\">",
"     GP160/120",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/17\">",
"     17",
"    </a>",
"    ]. In two studies, such antibodies were found in 70 and 73 percent of sera from HIV-infected patients with PHAT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. IgM antiidiotype antibodies directed against platelet anti-GPIIIa appears to directly regulate the degree of thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, anti-HIV antibodies that bind to normal control platelets were found in 50 percent of sera from patients with PHAT as compared with only 5 percent of sera from HIV-infected patients with normal platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/21\">",
"     21",
"    </a>",
"    ]. These and other observations suggest that molecular mimicry between HIV proteins and platelet",
"    <span class=\"nowrap\">",
"     GPIIb/IIIa",
"    </span>",
"    may be important in the pathogenesis of PHAT [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Macrophages in the reticuloendothelial system (primarily splenic) are the chief mediators of platelet destruction, binding to the Fc receptors on antibody- or immune complex-bound cells and eliminating them through phagocytosis. Abnormalities in Fc clearance in HIV infection may account for the lack of direct concordance between cell-bound antibody and cytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ineffective platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;In situ hybridization techniques have detected HIV transcripts in the megakaryocytes of patients with PHAT, demonstrating the ability of HIV to directly infect platelet progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Electron microscopy of megakaryocytes from HIV-infected individuals with thrombocytopenia clearly demonstrates ultrastructural abnormalities not encountered in noninfected patients; blebbing of the surface membrane and vacuolization of peripheral cytoplasm are the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/27\">",
"     27",
"    </a>",
"    ]. It is postulated that infection of these platelet precursors impairs subsequent development and maturity, leading to the observed reduction in platelet production. Other alterations in the bone marrow microenvironment may also contribute to poor platelet production [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Increased programmed cell death (apoptosis) of bone marrow megakaryocytes in HIV-infected patients has also been postulated as a contributor to thrombocytopenia. In one study, the degree of apoptosis in glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa-positive",
"    </span>",
"    megakaryocytes purified from the bone marrow of HIV-positive thrombocytopenic patients was inversely related to the circulating platelet count (p&lt;0.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/32\">",
"     32",
"    </a>",
"    ]. This observation suggests that, in patients with circulating antibodies cross-reacting against glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    there is increased apoptosis of megakaryocytes as well as increased peripheral destruction of platelets bearing these glycoproteins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Secondary causes of thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary causes of thrombocytopenia are generally the result of underlying opportunistic infections, malignancy, and co-morbid conditions resulting in hypersplenism (",
"    <a class=\"graphic graphic_table graphicRef81654 \" href=\"UTD.htm?1/35/1597\">",
"     table 1",
"    </a>",
"    ). Patients with HIV infection may also be more susceptible to certain medication-associated thrombocytopenias. As an example, a retrospective evaluation demonstrated a much higher frequency of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) among heparin-exposed patients with HIV. Specifically, 13 of 53 (25 percent) hospitalized HIV patients who received either unfractionated heparin or low molecular weight heparin met criteria for HIT compared with zero of 106 concurrently hospitalized and anticoagulated HIV-negative patients (OR 26; 95% CI 7.7-85) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) is a rare and potentially fatal cause of thrombocytopenia that must also be considered in the initial evaluation of HIV-infected patients with reduced platelet counts (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Thrombotic thrombocytopenic purpura'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment of PHAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the exclusion of secondary causes of thrombocytopenia and discontinuation of potentially marrow-suppressing medications, there are many therapies available for the management of HIV-associated thrombocytopenia. Individual circumstances dictate the necessity and acuity of therapy. As a result, therapeutic decisions should be made on a case-by-case basis, considering:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The patient's current platelet count",
"     </li>",
"     <li>",
"      The potential toxicities of therapy",
"     </li>",
"     <li>",
"      Other co-morbid conditions that increase the risk of bleeding complications (eg, hemophilia, metastatic malignancy)",
"     </li>",
"     <li>",
"      A spontaneous remission rate of almost 20 percent in patients with PHAT [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Zidovudine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (AZT) has been the mainstay of therapy of PHAT. Despite its well-recognized potential for suppression of myeloid and erythroid precursors, AZT increases platelet production in kinetic studies of HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/12\">",
"     12",
"    </a>",
"    ]. In a prospective evaluation of HIV-infected patients with thrombocytopenia (mean platelet count,",
"    <span class=\"nowrap\">",
"     53,000/microL;",
"    </span>",
"    range 25 to",
"    <span class=\"nowrap\">",
"     85,000/microL),",
"    </span>",
"    the platelet count rose by more than",
"    <span class=\"nowrap\">",
"     50,000/&micro;L",
"    </span>",
"    after eight weeks of AZT therapy (2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for two weeks followed by 1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for six weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/34\">",
"     34",
"    </a>",
"    ]. In another nonrandomized trial using AZT in a dose of 1.5",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    a persistent platelet count above",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    which represented at least a twofold increase in baseline platelet count, occurred in 15 of 34 patients (44 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While clinical responses have been described with many different doses of AZT, higher daily doses are associated with more prominent and durable elevations in platelet count. This was demonstrated in an open label, randomized, multi-institutional study which compared the efficacy of two doses of AZT (0.5 and 1.0",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    for six months) in HIV-infected patients with platelet counts below",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/36\">",
"     36",
"    </a>",
"    ]. The higher dose of AZT resulted in a higher percentage of patients with platelet counts above",
"    <span class=\"nowrap\">",
"     100,000/L",
"    </span>",
"    (39 versus 11 percent); in addition, mean platelet counts remained significantly higher after 6 months of treatment",
"    <span class=\"nowrap\">",
"     (98,000/microL",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     56,000/microL)",
"    </span>",
"    at the higher dose. The role of AZT in the therapy of patients with PHAT and AZT-resistant strains of HIV has not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other antiretroviral medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is less information on the impact of other antiretroviral medications or combination regimens on PHAT. A review of early experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    monotherapy showed a small but statistically significant increase of peripheral platelet counts within four weeks in more than 160 HIV-positive patients. Mean platelet counts at baseline and four weeks were 175,000 and",
"    <span class=\"nowrap\">",
"     197,000/microL,",
"    </span>",
"    respectively (p&lt;0.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite multiple reports and case series, there are no prospective, controlled trials documenting clinical improvements of PHAT in patients receiving any antiretroviral agent (nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors, or combination regimens) other than AZT.",
"   </p>",
"   <p>",
"    A number of complications of HIV infection have been reduced by the widespread use of highly active antiretroviral therapy (HAART), including the occurrence of opportunistic infections and Kaposi's sarcoma. HAART may also be associated with improvement in PHAT. Several retrospective studies support this observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, platelet counts rose significantly in all 18 patients with moderate degrees of thrombocytopenia (platelet count",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL),",
"      </span>",
"      with a mean increase of",
"      <span class=\"nowrap\">",
"       56,000/microL",
"      </span>",
"      within one month of the start of a protease inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In another study, which included 13 patients with severe thrombocytopenia (platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL),",
"      </span>",
"      median platelet counts increased significantly from 27,000 to 63,000 and",
"      <span class=\"nowrap\">",
"       86,000/microL",
"      </span>",
"      three and six months, respectively, after the initiation of HAART [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/39\">",
"       39",
"      </a>",
"      ]. Several different antiretroviral combinations were utilized in this series.",
"     </li>",
"     <li>",
"      In a third report, 15 patients with thrombocytopenia (platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL)",
"      </span>",
"      were treated with various combinations of antiretroviral regimens [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/40\">",
"       40",
"      </a>",
"      ]. All patients experienced sustained improvement in platelet counts during the first three months of therapy, even those with a prior history of antiretroviral therapy (13 of 15) and a history of failure to respond to AZT monotherapy for thrombocytopenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Declines in platelet counts have been reported in patients who discontinue antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=see_link\">",
"     \"Structured treatment interruptions in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of structured treatment interruption among HIV-infected individuals with undetectable viral loads and CD4 counts",
"      <span class=\"nowrap\">",
"       &gt;350/microL,",
"      </span>",
"      3 of 23 enrolled patients developed recurrent thrombocytopenia during the periodic discontinuations of combination antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another prospective investigation of 391 HIV patients with undetectable HIV viral loads at baseline, the likelihood of developing thrombocytopenia (ie, platelet count &lt;",
"      <span class=\"nowrap\">",
"       150,000/microL)",
"      </span>",
"      during 96 weeks of follow-up was significantly greater among patients randomly assigned to receive to intermittent antiretroviral therapy compared with those receiving continuous antiretroviral therapy (25.4 versus 9.8 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/42\">",
"       42",
"      </a>",
"      ]. Thrombocytopenia was detected at a median of nine weeks following the discontinuation of therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, our first line approach to PHAT is to include AZT at a minimum dose of 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the patient's multiagent antiretroviral regimen. Dose escalation of AZT to 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should be considered if there is no improvement in platelet counts following four to eight weeks of therapy. The use of additional therapies is based upon the severity of thrombocytopenia, evidence of bleeding (eg, petechiae, epistaxis, hematuria), and other coincident conditions such as coagulation factor deficiencies. Patients with clinical hemostatic defects or in whom surgery is imminent are often treated with either pooled immunoglobulins or specific anti-D antibody (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous immune globulin (IGIV, IVIG) produces dramatic, rapid improvements in platelet counts in the majority of patients with PHAT. A review of published cases described platelet counts exceeding",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    in almost 90 percent of patients after a single treatment with high-dose IGIV [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/43\">",
"     43",
"    </a>",
"    ]. Dosages typically ranged from 1 to 2",
"    <span class=\"nowrap\">",
"     g/kg;",
"    </span>",
"    many of these patients also received intercurrent steroids. IGIV is thought to saturate Fc receptors in the reticuloendothelial system, thereby preventing the destruction of platelets (and red blood cells) coated with antibodies or immune complexes.",
"   </p>",
"   <p>",
"    A prospective comparison between various IGIV regimens in non-HIV infected patients with ITP documented that 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    was as effective as higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/44\">",
"     44",
"    </a>",
"    ]. Responses in both ITP and PHAT are typically evident within days after the administration of IGIV. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response seen after therapy is typically transient and multiple repeated administrations may be required [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, the high cost, long infusion time (four to five hours), and limited supply of human immunoglobulin reduce the overall utility of this therapy for long-term management. Intravenous immunoglobulins remain a treatment of choice in situations requiring the rapid correction of low platelet counts, such as anticipated surgery or as an adjuvant to platelet transfusion during acute bleeding episodes.",
"   </p>",
"   <p>",
"    The administration of IGIV has not been associated with increased immunosuppression in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/45\">",
"     45",
"    </a>",
"    ]. Side effects are typically mild and include infusion-related fever, nausea, emesis, myalgia and hypotension. The immunoglobulin infusion does represent a substantial osmotic load and rates of infusion are necessarily slow. Some preparations are associated with the development of acute renal failure due to sucrose-induced osmotic injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anti-D immunoglobulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A component of IGIV, anti-Rh(D) (anti-D, WinRho&trade;), is effective only in non-splenectomized, Rh-positive patients in whom the immunoglobulin binds to the erythrocyte D antigen. These sensitized erythrocytes undergo immune-mediated clearance by the reticuloendothelial system. By competitively binding Fc receptors in the spleen, these anti-D-bound erythrocytes help reduce the destruction of antibody-coated platelets, thereby increasing circulating platelet counts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-D is an effective alternative to IGIV in patients with PHAT. A prospective evaluation of Rh-positive patients with PHAT demonstrated improved platelet counts in 9 of 14 patients 3 to 12 days after the initiation of therapy (12 to 25",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    intravenously on two consecutive days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/47\">",
"     47",
"    </a>",
"    ]. The platelet response to anti-D in PHAT is equivalent to that in HIV-negative patients with ITP [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-D is less expensive than high-dose IGIV and requires a shorter infusion time (typically less than five minutes). In addition, maintenance intramuscular administration of 6 to 13",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    per week of anti-D provided sustained responses in 85 percent of patients with ITP who had a prior response to intravenous infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results from a small, prospective, crossover design trial found that anti-D, compared with IVIG, produced a greater increase in platelet counts (77,000 versus",
"    <span class=\"nowrap\">",
"     29,000/microL)",
"    </span>",
"    and a longer duration of response (41 versus 19 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical starting dose of anti-D is 50",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    IV over three to five minutes. It may be administered as a single dose or in two divided doses on consecutive days. Doses may be escalated to a maximum of 80",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    based upon response. As noted above, hemolysis is an expected feature of anti-D therapy. A reduction in hemoglobin concentration of 0.5 to 2.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    is typical in the majority of patients; thus, this drug must be used cautiously in patients with concurrent anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In such patients, the initial dose can be reduced to 25 to 40",
"    <span class=\"nowrap\">",
"     microg/kg",
"    </span>",
"    with subsequent escalation based upon clinical response and the impact upon hemoglobin levels. Repeat infusions are commonly required after three to four weeks; the clinical response dictates the ideal interval between doses for each patient.",
"   </p>",
"   <p>",
"    According to unpublished data from WinRho clinical trials, intravascular hemolysis with associated anemia and renal insufficiency has been encountered in 0.7 percent of cases following the administration of WinRho",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/58/11175?source=see_link\">",
"     Rho(D) immune globulin",
"    </a>",
"    in the treatment of ITP. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Intravenous immunoglobulin and anti-D'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those patients with an inadequate response to antiretroviral agents alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    are two additional agents that may provide some benefit. The synthetic androgen danazol (400 to 800",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may raise the platelet count, although the documented experience in PHAT is limited. In one series, only 2 of 18 patients responded to danazol [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/51\">",
"     51",
"    </a>",
"    ]. Liver function abnormalities and other androgen-related phenomena may occur and warrant close monitoring.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (50 to 125",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    may be a better alternative. In one study, 9 of 11 patients (mean platelet count",
"    <span class=\"nowrap\">",
"     27,000/microL)",
"    </span>",
"    who had failed other medical interventions responded to dapsone; six of the nine had sustained platelet counts greater than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/52\">",
"     52",
"    </a>",
"    ]. The only major toxicity was a mild reduction (less than 7 percent) in hemoglobin secondary to hemolysis. The exact mechanism of activity remains uncertain although a competitive effect on red cell clearance by the reticuloendothelial system may be hypothesized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroids have demonstrated efficacy in HIV-associated thrombocytopenia. In a prospective evaluation of 24 patients (mean platelet count",
"    <span class=\"nowrap\">",
"     21,000/microL),",
"    </span>",
"    80 percent had a notable improvement in platelet counts and a lower incidence of bleeding after three weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/53\">",
"     53",
"    </a>",
"    ]. However, fewer than 10 percent had sustained resolution of thrombocytopenia after steroids were tapered. In addition, the risk of steroid-associated side effects was significant: 20 of 24 patients had clinical sequelae, including weight gain, cushingoid faces, oral candidiasis, dysphoria, acne, reactivation herpes simplex virus and proximal myopathy.",
"   </p>",
"   <p>",
"    Steroids may also accelerate the progression of Kaposi's sarcoma and increase the risk of many opportunistic processes, including Pneumocystis carinii pneumonia, tuberculosis, and cytomegalovirus infections. For these reasons, steroids can be recommended only for short term use in patients with PHAT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Interferon alfa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa is another option for the management of chronic PHAT. In a crossover trial of 12 patients with persistent thrombocytopenia despite treatment with AZT (mean baseline platelet count",
"    <span class=\"nowrap\">",
"     15,600/microL),",
"    </span>",
"    three million units of interferon-alfa given three times per week increased mean platelet counts more than fivefold (to",
"    <span class=\"nowrap\">",
"     82,000/microL)",
"    </span>",
"    within four weeks; there was no increase in platelet count during administration of placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/54\">",
"     54",
"    </a>",
"    ]. In another study of 13 patients, partial (platelet counts",
"    <span class=\"nowrap\">",
"     &gt;30,000/microL",
"    </span>",
"    for more than one month) or complete (platelet counts",
"    <span class=\"nowrap\">",
"     &gt;50,000/microL)",
"    </span>",
"    responses were noted in almost 70 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet counts tend to return to baseline levels within a few weeks after discontinuing therapy. Side effects including fever, chills, fatigue, headache, and depression occur in a significant proportion of recipients and complicate the use of this drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Vincristine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    in PHAT. In one series of patients with Kaposi's sarcoma, vincristine produced an increase in platelet count to above",
"    <span class=\"nowrap\">",
"     200,000/microL",
"    </span>",
"    in three patients with concurrent HIV-associated thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/56\">",
"     56",
"    </a>",
"    ]. Two of the three patients had sustained responses after six months, while the platelet count in the third patient fell to less than",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    after two months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent thrombocytopenia or dependence on repeat IGIV or anti-D infusions may benefit from splenectomy. An early series noted a persistent clinical response (platelet count",
"    <span class=\"nowrap\">",
"     &gt;150,000/microL)",
"    </span>",
"    in 10 of 10 patients treated with splenectomy (mean follow-up, 10 months; range, 2 to 44 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/14\">",
"     14",
"    </a>",
"    ]. In another prospective evaluation, mean platelet counts increased from 18,000 to",
"    <span class=\"nowrap\">",
"     223,000/microL",
"    </span>",
"    immediately after splenectomy in 68 patients; a sustained response after six months was noted in 82 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite some early reports of accelerated progression from HIV infection to AIDS after splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/58\">",
"     58",
"    </a>",
"    ], later data support the safety of this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. In one series, for example, there were no reported episodes of overwhelming postsplenectomy infection in a group of 14 patients followed prospectively for a mean observation time of 27 months [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients considering splenectomy should receive vaccinations against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis prior to surgery to reduce the risk of subsequent infection with these encapsulated organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link\">",
"     \"Immunizations in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Splenic irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less commonly employed than splenectomy, splenic irradiation is another option for patients refractory to standard interventions or those considered poor surgical candidates [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In a report of three patients unresponsive to other therapies, there were marked elevations in platelet counts after three to five weeks of biweekly low-dose splenic irradiation (1.0 Gy per dose for a cumulative total of 9 to 10 Gy) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/62\">",
"     62",
"    </a>",
"    ]. Based upon the absence of Howell-Jolly bodies on the postirradiation smears, the authors concluded that some splenic function was retained after the procedure, potentially reducing the risk for later overwhelming infection with encapsulated organisms.",
"   </p>",
"   <p>",
"    One problem with splenic irradiation is a short duration of response. In two series, only two of 27 patients had a stable platelet count at six months after therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Thrombopoietic growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PHAT, as compared with healthy control subjects, have markedly elevated levels of endogenous thrombopoietin (mean levels of 596 versus 95",
"    <span class=\"nowrap\">",
"     pg/mL)",
"    </span>",
"    and increased thrombopoietin receptor numbers (461 versus 207",
"    <span class=\"nowrap\">",
"     receptors/platelet)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dramatic increases in platelet counts in HIV-infected chimpanzees with baseline thrombocytopenia have been noted after the administration of recombinant human megakaryocyte growth and development factor [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/65\">",
"       65",
"      </a>",
"      ]. In addition, all six patients with AIDS-associated thrombocytopenia treated with eight doses of PEG-rHuMGDF normalized their platelet counts [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/66\">",
"       66",
"      </a>",
"      ]. However, this derivative of thrombopoietin is no longer clinically available.",
"     </li>",
"     <li>",
"      Interleukin-11 (Neumega&reg;) has been approved for patients with cancer-related thrombocytopenia and a trial piloting its use in patients with PHAT is planned.",
"     </li>",
"     <li>",
"      The role of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/17/11543?source=see_link\">",
"       eltrombopag",
"      </a>",
"      and other receptor agonists in the management of PHAT has not been clearly defined. Clinical trials evaluating the role of eltrombopag in thrombocytopenia patients with HIV and other comorbid conditions are currently underway. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"       \"Clinical applications of thrombopoietic growth factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ABNORMALITIES OF THE COAGULATION SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several abnormalities of the coagulation system that may be encountered in patients with HIV infection, including an increased propensity for the development of thrombosis, presence of antiphospholipid antibodies, abnormalities of several of the factors involved in the regulation of clotting, and thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. These are described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using prospective data gathered from more than 42,900 patients in the",
"    <span class=\"nowrap\">",
"     Adult/Adolescent",
"    </span>",
"    Spectrum of HIV Disease Surveillance Project, the incidence of venous thrombosis in HIV-infected patients was determined to be 2.6 instances per 1000 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/67\">",
"     67",
"    </a>",
"    ]. In this study, risk factors significantly associated with the development of thrombosis included age &gt;45 years, acute hospitalization, and the diagnosis of CMV retinitis or another opportunistic infection. Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    also appeared to have a heightened risk of venous thrombosis, while usage of other protease inhibitors was not significantly correlated with thrombotic events.",
"   </p>",
"   <p>",
"    A large case-control study of veterans demonstrated an increased occurrence of venous thromboembolism (VTE) among HIV-infected patients compared to age-, race-, and site-matched HIV-negative controls in both the pre- and post-HAART eras (11.3 versus 7.6 events per 1000 person years prior to 1996 and 5.7 versus 3.3 events per 1000 person years after 1996) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/68\">",
"     68",
"    </a>",
"    ]. The risk for VTE was significantly higher for HIV-infected patients before and after 1996 even after adjusting for other VTE risk factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H21#H21\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Acquired thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective assessment of data from the National Hospital Discharge Survey from 1996 to 2004, the odds ratio of developing a pulmonary embolism was 43 percent greater among HIV-infected patients in comparison to age-matched controls. HIV patients also had a 10 percent greater risk of developing deep vein thrombosis. The greatest increased risk for venous thromboembolic disease was demonstrated among patients between the ages of 21 and 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that have been implicated in the development of thrombotic complications in HIV-infected patients, in addition to opportunistic infections, malignancy, and an indwelling central venous catheter, include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/68,70-74\">",
"     68,70-74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower CD4 counts",
"     </li>",
"     <li>",
"      Elevated HIV viral loads",
"     </li>",
"     <li>",
"      Elevated levels of factor VIII and homocysteine",
"     </li>",
"     <li>",
"      Elevated lipid levels",
"     </li>",
"     <li>",
"      Increased tissue factor expression on circulating monocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/75\">",
"       75",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Presence of antiphospholipid antibodies (lupus anticoagulants or anticardiolipin antibodies) or autoimmune hemolytic anemia (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Antiphospholipid antibodies'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Acquired deficiencies of proteins S and C and antithrombin&nbsp;(see",
"      <a class=\"local\" href=\"#H22\">",
"       'Deficiency of proteins C and S'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) may be associated with both anticardiolipin antibodies (aCL) or lupus anticoagulants (LA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=see_link\">",
"     \"Pathogenesis of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticardiolipin antibodies (aCL) are a broad class of antibodies capable of binding acidic phospholipids. Elevated levels of aCL are often encountered in patients with chronic infections and have been described in as many as 64 percent of HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/76-78\">",
"       76-78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      LA are antibodies directed against plasma proteins bound to anionic phospholipids and have been found in some HIV-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The APS is associated with an increased propensity to arterial and venous thrombosis in HIV-negative as well as HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/70,81,82\">",
"     70,81,82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Deficiency of proteins C and S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired deficiencies of proteins S and C have been reported in association with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/70,82,83\">",
"     70,82,83",
"    </a>",
"    ], and may be related to the presence of acute opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/84\">",
"     84",
"    </a>",
"    ]. In one evaluation of 25 patients with HIV infection, reduced levels of free protein S were noted in over 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/85\">",
"     85",
"    </a>",
"    ]. Other investigators have failed to confirm this unusually high incidence, and have suggested that it may be an artifact due to high circulating levels of protein S-binding microparticles [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thrombotic thrombocytopenic purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) has been described among patients with HIV infection, although its incidence in the post-HAART era appears to be declining. Of over 6000 HIV-infected patients followed in a United States cohort study, the incidence of TTP was 0.009 and of HUS 0.069 per 100 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/87\">",
"     87",
"    </a>",
"    ]. Among the 362 patients recorded in the Oklahoma TTP-HUS registry, HIV infection was detected in six of the 326 adult patients (1.84 percent, 95% CI 0.68-4.0) who received documented HIV screening [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/88\">",
"     88",
"    </a>",
"    ]. None of the pediatric cases (age &lt;20 years) had evidence of HIV infection.",
"   </p>",
"   <p>",
"    Patients who developed thrombotic microangiopathy, compared with those who did not, were more likely to have a lower CD4+ lymphocyte count (197 versus",
"    <span class=\"nowrap\">",
"     439/microL),",
"    </span>",
"    higher mean log HIV-1 RNA levels (4.6 versus 3.3 log",
"    <span class=\"nowrap\">",
"     copies/mL),",
"    </span>",
"    and a history of acquired immunodeficiency syndrome (AIDS) and hepatitis C infection.",
"   </p>",
"   <p>",
"    The diagnosis of TTP-HUS should be considered in all HIV-infected patients presenting with thrombocytopenia and anemia. However, opportunistic infection with associated thrombocytopenia should be excluded, along with a search for enterohemorrhagic Escherichia coli (E. coli O157:H7) in stool cultures. Of interest, in one study HIV+ patients with TTP demonstrated a more rapid response to fresh frozen plasma infusion and steroids than did HIV- patients, and none required plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/89\">",
"     89",
"    </a>",
"    ]. In another series of 30 HIV-infected English patients with TTP, the combination of plasma exchange",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    steroids with the prompt initiation or reinitiation of combination antiretroviral therapy was associated with clinical remission among eight patients newly diagnosed HIV and four others who had relapsed during a period of non-adherence to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/11/14522/abstract/90\">",
"     90",
"    </a>",
"    ]. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Plasma exchange procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link&amp;anchor=H112794614#H112794614\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\", section on 'HIV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Low platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low platelet count is a common finding in individuals infected with HIV, affecting approximately 40 percent of patients during the course of their illness. There are two general causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Primary cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary HIV-associated thrombocytopenia (PHAT) is the most common cause of low platelet counts encountered in HIV-infected patients. Clinically, PHAT is similar to classic immune (idiopathic) thrombocytopenic purpura except that splenomegaly is more commonly noted in patients with PHAT. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Primary HIV-associated thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Secondary causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary causes of thrombocytopenia are generally the result of underlying opportunistic infections, malignancy, co-morbid conditions resulting in hypersplenism, and medication side-effects (",
"    <a class=\"graphic graphic_table graphicRef81654 \" href=\"UTD.htm?1/35/1597\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Secondary causes of thrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Coagulation abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several abnormalities of the coagulation system that may be encountered in patients with HIV infection. These include the following. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Abnormalities of the coagulation system'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An increased propensity for thrombosis",
"     </li>",
"     <li>",
"      Presence of antiphospholipid antibodies",
"     </li>",
"     <li>",
"      Abnormalities of several of the factors involved in the regulation of clotting",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/1\">",
"      Morris L, Distenfeld A, Amorosi E, Karpatkin S. Autoimmune thrombocytopenic purpura in homosexual men. Ann Intern Med 1982; 96:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/2\">",
"      Karpatkin S, Nardi M, Green D. Platelet and coagulation defects associated with HIV-1-infection. Thromb Haemost 2002; 88:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/3\">",
"      Sloand EM, Klein HG, Banks SM, et al. Epidemiology of thrombocytopenia in HIV infection. Eur J Haematol 1992; 48:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/4\">",
"      Galli M, Musicco M, Gervasoni C, et al. No evidence of a higher risk of progression to AIDS in patients with HIV-1-related severe thrombocytopenia. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/5\">",
"      Wandt H, Frank M, Ehninger G, et al. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood 1998; 91:3601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/6\">",
"      Vannappagari V, Nkhoma ET, Atashili J, et al. Prevalence, severity, and duration of thrombocytopenia among HIV patients in the era of highly active antiretroviral therapy. Platelets 2011; 22:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/7\">",
"      Marks KM, Clarke RM, Bussel JB, et al. Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/8\">",
"      Firnhaber C, Smeaton L, Saukila N, et al. Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas. Int J Infect Dis 2010; 14:e1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/9\">",
"      Ehmann WC, Rabkin CS, Eyster ME, Goedert JJ. Thrombocytopenia in HIV-infected and uninfected hemophiliacs. Multicenter Hemophilia Cohort study. Am J Hematol 1997; 54:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/10\">",
"      Peltier JY, Lambin P, Doinel C, et al. Frequency and prognostic importance of thrombocytopenia in symptom-free HIV-infected individuals: a 5-year prospective study. AIDS 1991; 5:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/11\">",
"      Glatt AE, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis 1995; 21:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/12\">",
"      Ballem PJ, Belzberg A, Devine DV, et al. Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/13\">",
"      Cole JL, Marzec UM, Gunthel CJ, et al. Ineffective platelet production in thrombocytopenic human immunodeficiency virus-infected patients. Blood 1998; 91:3239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/14\">",
"      Walsh C, Krigel R, Lennette E, Karpatkin S. Thrombocytopenia in homosexual patients. Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 103:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/15\">",
"      Bettaieb A, Oksenhendler E, Fromont P, et al. Immunochemical analysis of platelet autoantibodies in HIV-related thrombocytopenic purpura: a study of 68 patients. Br J Haematol 1989; 73:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/16\">",
"      Karpatkin S, Nardi M, Lennette ET, et al. Anti-human immunodeficiency virus type 1 antibody complexes on platelets of seropositive thrombocytopenic homosexuals and narcotic addicts. Proc Natl Acad Sci U S A 1988; 85:9763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/17\">",
"      Bettaieb A, Fromont P, Louache F, et al. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins in HIV-related immune thrombocytopenic purpura. Blood 1992; 80:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/18\">",
"      Karpatkin S, Nardi M. Autoimmune anti-HIV-1gp120 antibody with antiidiotype-like activity in sera and immune complexes of HIV-1-related immunologic thrombocytopenia. J Clin Invest 1992; 89:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/19\">",
"      Nardi M, Tomlinson S, Greco MA, Karpatkin S. Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia. Cell 2001; 106:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/20\">",
"      Koefoed K, Ditzel HJ. Identification of talin head domain as an immunodominant epitope of the antiplatelet antibody response in patients with HIV-1-associated thrombocytopenia. Blood 2004; 104:4054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/21\">",
"      Gonzalez-Conejero R, Rivera J, Rosillo MC, et al. Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts. Br J Haematol 1996; 93:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/22\">",
"      Bettaieb A, Oksenhendler E, Duedari N, Bierling P. Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa (CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 1996; 103:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/23\">",
"      Nardi M, Karpatkin S. Antiidiotype antibody against platelet anti-GPIIIa contributes to the regulation of thrombocytopenia in HIV-1-ITP patients. J Exp Med 2000; 191:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/24\">",
"      Li Z, Nardi MA, Karpatkin S. Role of molecular mimicry to HIV-1 peptides in HIV-1-related immunologic thrombocytopenia. Blood 2005; 106:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/25\">",
"      Bender BS, Frank MM, Lawley TJ, et al. Defective reticuloendothelial system Fc-receptor function in patients with acquired immunodeficiency syndrome. J Infect Dis 1985; 152:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/26\">",
"      Grosset&ecirc;te B, Viard JP, Lehuen A, et al. Impaired Fc alpha receptor expression is linked to increased immunoglobulin A levels and disease progression in HIV-1-infected patients. AIDS 1995; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/27\">",
"      Zucker-Franklin D, Cao YZ. Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA. Proc Natl Acad Sci U S A 1989; 86:5595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/28\">",
"      Louache F, Bettaieb A, Henri A, et al. Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura. Blood 1991; 78:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/29\">",
"      Chelucci C, Federico M, Guerriero R, et al. Productive human immunodeficiency virus-1 infection of purified megakaryocytic progenitors/precursors and maturing megakaryocytes. Blood 1998; 91:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/30\">",
"      Bahner I, Kearns K, Coutinho S, et al. Infection of human marrow stroma by human immunodeficiency virus-1 (HIV-1) is both required and sufficient for HIV-1-induced hematopoietic suppression in vitro: demonstration by gene modification of primary human stroma. Blood 1997; 90:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/31\">",
"      Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998; 91:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/32\">",
"      Zauli G, Catani L, Gibellini D, et al. Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia. Br J Haematol 1996; 92:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/33\">",
"      Thompson GR 3rd, Lawrence VA, Crawford GE. HIV infection increases the risk of heparin-induced thrombocytopenia. Clin Infect Dis 2007; 45:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/34\">",
"      Zidovudine for the treatment of thrombocytopenia associated with human immunodeficiency virus (HIV). A prospective study. The Swiss Group for Clinical Studies on the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med 1988; 109:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/35\">",
"      Oksenhendler E, Bierling P, Ferchal F, et al. Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 110:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/36\">",
"      Landonio G, Cinque P, Nosari A, et al. Comparison of two dose regimens of zidovudine in an open, randomized, multicentre study for severe HIV-related thrombocytopenia. AIDS 1993; 7:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/37\">",
"      Schacter LP, Rozencweig M, Beltangady M, et al. Effects of therapy with didanosine on hematologic parameters in patients with advanced human immunodeficiency virus disease. Blood 1992; 80:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/38\">",
"      Maness LJ, Blair DC, Newman N, Coyle TE. Elevation of platelet counts associated with indinavir treatment in human immunodeficiency virus-infected patients. Clin Infect Dis 1998; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/39\">",
"      Arranz Caso JA, Sanchez Mingo C, Garcia Tena J. Effect of highly active antiretroviral therapy on thrombocytopenia in patients with HIV infection. N Engl J Med 1999; 341:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/40\">",
"      Carbonara S, Fiorentino G, Serio G, et al. Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors. J Infect 2001; 42:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/41\">",
"      Ananworanich J, Phanuphak N, Nuesch R, et al. Recurring thrombocytopenia associated with structured treatment interruption in patients with human immunodeficiency virus infection. Clin Infect Dis 2003; 37:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/42\">",
"      Bouldouyre MA, Charreau I, Marchou B, et al. Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trial. J Acquir Immune Defic Syndr 2009; 52:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/43\">",
"      Pollak AN, Janinis J, Green D. Successful intravenous immune globulin therapy for human immunodeficiency virus-associated thrombocytopenia. Arch Intern Med 1988; 148:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/44\">",
"      Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/45\">",
"      Holzman RS, Walsh CM, Karpatkin S. Risk for the acquired immunodeficiency syndrome among thrombocytopenic and nonthrombocytopenic homosexual men seropositive for the human immunodeficiency virus. Ann Intern Med 1987; 106:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/46\">",
"      Ware RE, Zimmerman SA. Anti-D: mechanisms of action. Semin Hematol 1998; 35:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/47\">",
"      Oksenhendler E, Bierling P, Brossard Y, et al. Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood 1988; 71:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/48\">",
"      Scaradavou A, Woo B, Woloski BM, et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/49\">",
"      Gringeri A, Cattaneo M, Santagostino E, Mannucci PM. Intramuscular anti-D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura. Br J Haematol 1992; 80:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/50\">",
"      Scaradavou A, Cunningham-Rundles S, Ho JL, et al. Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. Am J Hematol 2007; 82:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/51\">",
"      Oksenhendler E, Bierling P, Farcet JP, et al. Response to therapy in 37 patients with HIV-related thrombocytopenic purpura. Br J Haematol 1987; 66:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/52\">",
"      Durand JM, Lef&egrave;vre P, Hovette P, et al. Dapsone for thrombocytopenic purpura related to human immunodeficiency virus infection. Am J Med 1991; 90:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/53\">",
"      Abrams DI, Kiprov DD, Goedert JJ, et al. Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia. Ann Intern Med 1986; 104:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/54\">",
"      Marroni M, Gresele P, Landonio G, et al. Interferon-alpha is effective in the treatment of HIV-1-related, severe, zidovudine-resistant thrombocytopenia. A prospective, placebo-controlled, double-blind trial. Ann Intern Med 1994; 121:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/55\">",
"      Northfelt DW, Charlebois ED, Mirda MI, et al. Continuous low-dose interferon-alpha therapy for HIV-related immune thrombocytopenic purpura. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/56\">",
"      Mintzer DM, Real FX, Jovino L, Krown SE. Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1985; 102:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/57\">",
"      Oksenhendler E, Bierling P, Chevret S, et al. Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood 1993; 82:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/58\">",
"      Barbui T, Cortelazzo S, Minetti B, et al. Does splenectomy enhance risk of AIDS in HIV-positive patients with chronic thrombocytopenia? Lancet 1987; 2:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/59\">",
"      Kemeny MM, Cooke V, Melester TS, et al. Splenectomy in patients with AIDS and AIDS-related complex. AIDS 1993; 7:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/60\">",
"      Aboolian A, Ricci M, Shapiro K, et al. Surgical treatment of HIV-related immune thrombocytopenia. Int Surg 1999; 84:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/61\">",
"      Lord RV, Coleman MJ, Milliken ST. Splenectomy for HIV-related immune thrombocytopenia: comparison with results of splenectomy for non-HIV immune thrombocytopenic purpura. Arch Surg 1998; 133:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/62\">",
"      Needleman SW, Sorace J, Poussin-Rosillo H. Low-dose splenic irradiation in the treatment of autoimmune thrombocytopenia in HIV-infected patients. Ann Intern Med 1992; 116:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/63\">",
"      Soum F, Trille JA, Auvergnat JC, et al. Low-dose splenic irradiation in the treatment of immune thrombocytopenia in HIV-infected patients. Int J Radiat Oncol Biol Phys 1998; 41:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/64\">",
"      Blauth J, Fisher S, Henry D, Nichini F. The role of splenic irradiation in treating HIV-associated immune thrombocytopenia. Int J Radiat Oncol Biol Phys 1999; 45:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/65\">",
"      Harker LA, Marzec UM, Novembre F, et al. Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor. Blood 1998; 91:4427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/66\">",
"      Harker LA. Physiology and clinical applications of platelet growth factors. Curr Opin Hematol 1999; 6:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/67\">",
"      Sullivan PS, Dworkin MS, Jones JL, Hooper WC. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000; 14:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/68\">",
"      Fultz SL, McGinnis KA, Skanderson M, et al. Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans. Am J Med 2004; 116:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/69\">",
"      Malek J, Rogers R, Kufera J, Hirshon JM. Venous thromboembolic disease in the HIV-infected patient. Am J Emerg Med 2011; 29:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/70\">",
"      Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Clin Infect Dis 2004; 39:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/71\">",
"      Saif MW, Bona R, Greenberg B. AIDS and thrombosis: retrospective study of 131 HIV-infected patients. AIDS Patient Care STDS 2001; 15:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/72\">",
"      Klein SK, Slim EJ, de Kruif MD, et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/73\">",
"      Ahonkhai AA, Gebo KA, Streiff MB, et al. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008; 48:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/74\">",
"      Crum-Cianflone NF, Weekes J, Bavaro M. Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era. AIDS Patient Care STDS 2008; 22:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/75\">",
"      Funderburg NT, Mayne E, Sieg SF, et al. Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood 2010; 115:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/76\">",
"      Stimmler MM, Quismorio FP Jr, McGehee WG, et al. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med 1989; 149:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/77\">",
"      Abuaf N, Laperche S, Rajoely B, et al. Autoantibodies to phospholipids and to the coagulation proteins in AIDS. Thromb Haemost 1997; 77:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/78\">",
"      Martinez V, Diemert MC, Braibant M, et al. Anticardiolipin antibodies in HIV infection are independently associated with antibodies to the membrane proximal external region of gp41 and with cell-associated HIV DNA and immune activation. Clin Infect Dis 2009; 48:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/79\">",
"      Bloom EJ, Abrams DI, Rodgers G. Lupus anticoagulant in the acquired immunodeficiency syndrome. JAMA 1986; 256:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/80\">",
"      Cohen AJ, Philips TM, Kessler CM. Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med 1986; 104:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/81\">",
"      Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/82\">",
"      Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/83\">",
"      Bissuel F, Berruyer M, Causse X, et al. Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr 1992; 5:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/84\">",
"      Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/85\">",
"      Stahl CP, Wideman CS, Spira TJ, et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/86\">",
"      Gris JC, Toulon P, Brun S, et al. The relationship between plasma microparticles, protein S and anticardiolipin antibodies in patients with human immunodeficiency virus infection. Thromb Haemost 1996; 76:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/87\">",
"      Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39 Suppl 5:S267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/88\">",
"      Benjamin M, Terrell DR, Vesely SK, et al. Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis 2009; 48:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/89\">",
"      Novitzky N, Thomson J, Abrahams L, et al. Thrombotic thrombocytopenic purpura in patients with retroviral infection is highly responsive to plasma infusion therapy. Br J Haematol 2005; 128:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/11/14522/abstract/90\">",
"      Hart D, Sayer R, Miller R, et al. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura--favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol 2011; 153:515.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6679 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-50E636C042-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14522=[""].join("\n");
var outline_f14_11_14522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Primary HIV-associated thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Reduced platelet survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ineffective platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Secondary causes of thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment of PHAT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Zidovudine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other antiretroviral medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anti-D immunoglobulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Interferon alfa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Vincristine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Splenic irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ABNORMALITIES OF THE COAGULATION SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Deficiency of proteins C and S",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thrombotic thrombocytopenic purpura",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Low platelet count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Primary cause",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Secondary causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6679\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6679|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/35/1597\" title=\"table 1\">",
"      Causes of thrombocytopenia HIV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/0/44039?source=related_link\">",
"      Hematologic manifestations of HIV infection: Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/16/35081?source=related_link\">",
"      Pathogenesis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/51/10039?source=related_link\">",
"      Structured treatment interruptions in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_11_14523="Milk allergy presentation";
var content_f14_11_14523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Presentation of cow's milk allergy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        IgE-mediated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mixed IgE and non-IgE mediated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-IgE mediated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylaxis",
"       </td>",
"       <td>",
"        Eosinophilic enteropathies",
"       </td>",
"       <td>",
"        Dietary protein enteropathies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urticaria and angioedema",
"       </td>",
"       <td>",
"        Atopic dermatitis",
"       </td>",
"       <td>",
"        Gastroesophageal reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immediate oropharyngeal and gastrointestinal reactions",
"       </td>",
"       <td>",
"        Asthma",
"       </td>",
"       <td>",
"        Colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food-associated, exercise-induced anaphylaxis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Heiner syndrome (pulmonary hemosiderosis)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14523=[""].join("\n");
var outline_f14_11_14523=null;
var title_f14_11_14524="WHO GCTs";
var content_f14_11_14524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of GCTs according to tumor markers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Tumor type",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Marker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        <sub>",
"         &beta;",
"        </sub>",
"        -HCG",
"       </td>",
"       <td class=\"subtitle2\">",
"        AFP",
"       </td>",
"       <td class=\"subtitle2\">",
"        PLAP",
"       </td>",
"       <td class=\"subtitle2\">",
"        c-Kit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pure germinoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Germinoma (syncytiotrophoblastic)",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endodermal sinus tumor",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Choriocarcinoma",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Embryonal carcinoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mixed GCT",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mature teratoma",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immature teratoma",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein;",
"     <sub>",
"      &beta;",
"     </sub>",
"     -HCG:",
"     <sub>",
"      &beta;",
"     </sub>",
"     -human chorionic gonadotropin; GCT: germ cell tumor; PLAP: placental alkaline phosphatase.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Louis DN, Ohgaki H, Wiesterl O, et al. World Health Organization Classification of Tumours of the Central Nervous System, 3rd Edition, IARC Press, Lyon, 2007. Copyright &copy; 2007 IARC Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14524=[""].join("\n");
var outline_f14_11_14524=null;
var title_f14_11_14525="HRT and colorectal CA WHI";
var content_f14_11_14525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hormone replacement therapy reduces rates of invasive colorectal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 383px; height: 221px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the Women's Health Initiative, combined estrogen-progestin replacement therapy was associated with a significant reduction in the cumulative hazard of invasive colorectal cancer (hazard ratio 0.56, unadjusted 95 percent CI 0.38 to 0.81).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Estrogen and progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14525=[""].join("\n");
var outline_f14_11_14525=null;
var title_f14_11_14526="Staging fallopian cancer";
var content_f14_11_14526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F60565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F60565&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging fallopian tube cancer (TNM and International Federation of Gynecology and Obstetrics)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Primary tumor (T)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Primary tumor cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No evidence of primary tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tis&bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Carcinoma in situ (limited to tubal mucosa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        I",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor limited to the fallopian tube(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to one tube, without penetrating the serosal surface; no ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to both tubes, without penetrating the serosal surface; no ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T1c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Tumor limited to one or both tubes with extension onto or through the tubal serosa, or with malignant cells in ascites or peritoneal washings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T2",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        II",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor involves one or both fallopian tubes with pelvic extension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Extension and/or metastasis to the uterus and/or ovaries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Extension to other pelvic structures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T2c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Pelvic extension with malignant cells in ascites or peritoneal washings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        T3",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        III",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"2\">",
"        Tumor involves one or both fallopian tubes, with peritoneal implants outside the pelvis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3a",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIA",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Microscopic peritoneal metastasis outside the pelvis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3b",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIB",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        T3c",
"       </td>",
"       <td class=\"sublist_other\">",
"        IIIC",
"       </td>",
"       <td class=\"sublist_other\" colspan=\"2\">",
"        Peritoneal metastasis outside the pelvis and more than 2 cm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Regional lymph nodes (N)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NX",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        Regional lymph nodes cannot be assessed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        IIIC",
"       </td>",
"       <td colspan=\"2\">",
"        Regional lymph node metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Distant metastasis (M)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        TNM categories",
"       </td>",
"       <td class=\"subtitle2\">",
"        FIGO stages",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M0",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td colspan=\"2\">",
"        No distant metastasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M1",
"       </td>",
"       <td>",
"        IV",
"       </td>",
"       <td colspan=\"2\">",
"        Distant metastasis (excludes metastasis within the peritoneal cavity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Anatomic stage/prognostic groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage 0&bull;",
"       </td>",
"       <td>",
"        Tis",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage I",
"       </td>",
"       <td>",
"        T1",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IA",
"       </td>",
"       <td>",
"        T1a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IB",
"       </td>",
"       <td>",
"        T1b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IC",
"       </td>",
"       <td>",
"        T1c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage II",
"       </td>",
"       <td>",
"        T2",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIA",
"       </td>",
"       <td>",
"        T2a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIB",
"       </td>",
"       <td>",
"        T2b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIC",
"       </td>",
"       <td>",
"        T2c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage III",
"       </td>",
"       <td>",
"        T3",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIA",
"       </td>",
"       <td>",
"        T3a",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IIIB",
"       </td>",
"       <td>",
"        T3b",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Stage IIIC",
"       </td>",
"       <td>",
"        T3c",
"       </td>",
"       <td>",
"        N0",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        N1",
"       </td>",
"       <td>",
"        M0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stage IV",
"       </td>",
"       <td>",
"        Any T",
"       </td>",
"       <td>",
"        Any N",
"       </td>",
"       <td>",
"        M1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Liver capsule metastasis is T3/Stage III; liver parenchymal metastasis M1/Stage IV. Pleural effusion must have positive cytology for M1/Stage IV.",
"     <br>",
"      &bull; FIGO no longer includes Stage 0 (Tis).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14526=[""].join("\n");
var outline_f14_11_14526=null;
var title_f14_11_14527="Pars planitis";
var content_f14_11_14527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F60574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F60574&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pars planitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The peripheral retinal vessels have a whitish exudate adjacent to them. This periphlebitis is sometimes seen in an inflammatory condition known as pars planitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_11_14527=[""].join("\n");
var outline_f14_11_14527=null;
